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Humoralism was an old medical philosophy according to which health and disease 
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Even though the four humors theory was much later displaced by modern medicine 
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1.1.1 Huntington’s disease discovery and epidemiology
Huntington’s disease is an autosomal dominant neurodegenerative disease that mani-
fests through motor and psychiatric symptoms. Huntington’s disease was first described 
and named after George Huntington in 1872; who in his paper “On Chorea” described 
the major aspects of  the disease [1]. However, it was not until 1983 when the disease was 
first mapped to a restriction fragment length polymorphism marker (RFLP) (D4S10/
G8) [2] on chromosome 4 and it took 10 years more (1993) before it was linked to “in-
teresting transcript 15” (IT15) following which the HD gene was identified and isolated 
[3]. Since current knowledge about the human genome was unavailable at the time, the 
long search for the identification of  the disease gene was further limited by the telomeric 
location of  the RFLP marker, the physical distance as well as uncertain recombination 
frequencies between the marker and the disease locus [4,5]. HD population prevalence 
exhibits significant geographic differences depending on local, past migration patterns 
and ethnicity. The disease is most prominent in Western European populations with a 
rate of  occurrence of  5-10 in 100.000, a prevalence of  approximately 1 in 10.000 in Cau-
casian populations [6,7] and is least frequent in Japanese, Chinese, Finnish and African 
descent individuals [8]. However, as suggested by Evans et al., the disease prevalence has 
risen significantly in the last decades and it was found that for UK the number of  HD 
patients was 12.3 per 100.000 [9].  Localized geographic areas exhibit very low as well 
as very high prevalence with the most notable example being the population of  Lake 
Maracaibo in Venezuela which was also originally used to identify the disease gene [10]. 
1.1.2 Huntington’s disease genetics
Huntington’s disease is caused by an expanded CAG repeat in the HTT gene. Individu-
als that carry a CAG repeat higher than 35 are the ones that will most likely develop the 
disease symptoms at some point during their lifetime [11]. People with 36-39 repeats are 
known to carry a reduced penetrance allele and they may develop the disease rather later 




onset takes place between 35 and 50 years old [13]. However, symptom onset can occur 
at any time during the carrier’s lifetime and is inversely correlated to the CAG expan-
sion length. As a result, people with 40 repeats or more will develop the disease and 
when the repeat exceeds 50 symptoms may develop as early as childhood. The elongated 
CAG tract results in a mutant huntingtin protein with an elongated polyglutamine tract 
that is associated with protein aggregation and toxic gain-of-function properties [14]. 
During meiotic transmission, the HD repeat is unstable in more than 80 % of  the cases 
(increases and decreases) while the largest increases are seen in paternal transmissions 
[15]. This meiotic instability leads to genetic anticipation of  the disorder (increasing 
intergenerational disease severity) but also to the generation of  de-novo HD mutation 
carriers from unaffected parents; especially from parents which exhibited an increased 
glutamine repeat number and within the intermediate repeat area of  the disease (27-35 
CAGs) [16,17]. Nevertheless, the HD gene mutation only explains about 50-77 % of  the 
variance in the age of  symptom onset and scientists are continuously looking for genetic 
as well as environmental modifiers of  disease onset [18,19]. Several genetic modifiers 
have been identified that further influence the trinucleotide repeats instability as well 
as the age of  onset of  the disease. Such genetic modifiers influence the manifestation 
of  disease phenotypes and partially explain the variability and degree to which these 
symptoms develop [18,20,21]. Apart from genetic modifiers, there are also specific fac-
tors that lead     to the unstable transmission of  the, disease causing, trinucleotide repeat 
expansion and include toxic oxidation which is known to cause progressive age-depen-
dent expansions [22,23] as well as population specific haplotypes made up of  sets of  sin-
gle nucleotide polymorphisms [24]. On the other hand, genetic modifiers that influence 
the disease onset include functional polymorphisms in key genes involved in neuronal 
processes, the processing of  huntingtin itself, gene transcription but also metabolism. 
Examples of  affected genes include the a) kainate receptor GluR6 [25] b) glutamate re-
ceptor, ionotropic, N-methyl-d-aspartate – GRIN2A/2B [26] c) gene transcription factor 
TP53 [27] d) the Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Al-
pha (PPARGC1A) transcription factor that is involved in regulating energy metabolism 
genes [28,29]. Finally, in a recent very large genome wide association study two different 
chromosomal loci were discovered (chromosomes 8 and 15) that exhibited independent 
effects of  disease onset acceleration and/or delay [30]. The functional variants within 
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the above two chromosomal loci are thought to affect genes involved in DNA synthe-
sis and repair, mitochondrial energetics and oxidative stress (FAN1, MTMR10, RRM2B, 
UBR5). The presence of  all the above genetic differences in HD mutation carriers shows 
that detailed genotypic information will be required in order to efficiently address the 
manifested disease symptom variability.
1.1.3 Huntington’s disease motor symptoms
One of  the most prominent features of  HD is the movement disorder known as chorea 
[31]. Chorea is characterized by hyperkinetic dance like movements and ranges from 
random, exaggerated gestures and expressions to continuous and violent movements. 
Huntington’s disease patients are also characterized by non-choreatic, hypokinetic 
movements such as bradykinesia and dystonia. Hypokinetic movements are usually 
more prominent during middle and late stages of  the disease while, on the other hand, 
hyperkinetic movements are usually present at early to middle stages of  the disease. Spe-
cifically, as the functional capacity of  patients declines, the presence of  chorea lessens 
and the presence of  dystonia is intensified [32]. Additional motor symptoms include the 
slowness of  movements (bradykinesia), rigidity and clumsiness. Aside from chroreatic 
or dystonic motor symptoms patients also exhibit skeletal muscle wasting and weight 
loss (see 1.2.4) [33]. The above two observations take place irrespective of  the fact that 
HD patients receive a steady caloric intake [34]. HD patients further exhibit ocular ab-
normalities such as the inability to suppress reflexive saccades to a new optical stim-
ulus, and are characterized by delayed initiation of  voluntary saccades (reflexive and 
voluntary eye control respectively) [35]. These ocular dysfunctions can be in turn linked 
to potentially affected brain areas since it has been shown that saccadic eye movement 
control is partially controlled by the hippocampus, the inferior parietal lobule and the 
prefrontal cortex [36,37]. Finally, in subsequent and more advanced stages of  the disease 
the patients are exhibiting dysarthria (speech problems), dysphagia (swallowing difficul-
ties) and balance disturbances, with the latter two problems constituting potential death 




1.1.4 Huntington’s disease cognitive and psychiatric symptoms
HD is characterized by cognitive and psychiatric symptoms such as depression, irritabil-
ity, apathy, anxiety and dementia. The above symptoms are usually evident well before 
the onset of  any motor symptoms and get significantly worse over time. Nevertheless, 
psychiatric symptoms do not always correlate with cognitive and motor aspects of  the 
disease and specific symptoms are sometimes more highly associated with certain dis-
ease stages, such as the manifestation of  depression at the same time or after onset of  
motor symptoms [42,43]. Previous studies have identified that depression is a significant 
component of  the prognostic signature of  HD and that such affective disorders can ap-
pear as early as 20 years before choreatic and cognitive symptom onset [44]. Another 
study of  depression in HD has reported that over 40 % percent of  HD patients had 
significant symptoms of  depression and over 50 % had previously received treatment for 
depression [45]. These numbers are significantly higher than the prevalence of  depres-
sion in the general population (8-12 %) [46]. The exact reason behind the high number 
of  reports of  depression in HD is not clear. However, it has been hypothesized that apart 
from potential perturbed biological pathways this could be also due to the adjustment 
of  these patients to the idea that they suffer from a disabling, terminally ill disorder 
[47,48]. Moreover, anxiety and irritability have also been reported in HD at  a preva-
lence  varying from 34-61% and 38-73% respectively [49] which is also much higher 
than the reported lifetime prevalence of  any other anxiety disorder as reported from the 
World Mental Health surveys[50]. HD patients are likewise often characterized by ap-
athy and specifically reduced energy and lack of  drive. It has been proposed that in HD 
and other neuropsychiatric diseases, apathy is distinct from depression and  associated 
with disinhibition and aberrant motor behavior, in contrast to anxiety and irritability 
which characterize depression [51]. Finally, obsessive and compulsive symptoms as well 
as psychotic symptoms have also been reported in HD mutation carriers, even though at 
a much lower prevalence (10-52 % and 3-11% respectively) [43,49].
1.2 Huntington’s disease neuropathology 
Huntington’s disease is characterized by atrophy of  the cerebral cortex and the striatum 
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and HD patients are known to lose up to 40% of  their brain volume compared to healthy 
individuals [52,53]. Neurodegeneration affects mostly the medium spiny projection neu-
rons of  the striatum while the interneurons are relatively spared [54]. The neurodegen-
eration mechanism of  the mutant huntingtin protein however appears to be complex 
and neuronal death does not always correlate to huntingtin nuclear inclusions [55]. One 
of  the most used methods to classify HD neuropathological severity is the Vonsattel 
ascending severity order grading system (Grades 0-4) that was formulated using post-
mortem brain specimens in order to identify the microscopic and macroscopic changes 
taking place in mutation carrier brain tissue [56]. Vonsattel et al. reported a caudate 
nucleus neuronal loss of  50-95% from grades 1-4 and a big increase of  astrocytic popula-
tion during grades 2-4. The authors also reported that the earliest changes were found in 
the medial paraventricular areas of  the caudate nucleus and dorsal part of  the putamen 
as well as the fact that anatomical changes were usually lagging behind the clinical symp-
toms something that has also been confirmed by later studies [57,58]. Apart from the 
neuronal degeneration pattern that is evident in the striatum of  HD patients, other areas 
are affected too such as the substantia nigra, globus pallidus, thalamus and cerebellum 
[59]. The multiplicity and the variable degree of  degeneration of  the affected brain areas 
constitute the basis for the diverse clinical phenotype and disease progression rates the 
patients exhibit. The latter assumption has been supported by imaging studies, which 
have revealed a widespread brain tissue degeneration and significant volume reductions 
in almost all brain areas; occurring even in early stage patients [60-63].
1.2.1 Huntingtin protein structure and function 
Wild type Huntingtin (Htt) protein is 348 kDa, expressed ubiquitously and its highest 
levels are found in the brain and the testis [3,64-66]. The exact 3D and molecular struc-
ture of  the protein has not been yet achieved due to the high molecular weight of  the 
protein and the problems this causes in X-ray crystallography. Currently, in an ongoing 
attempt to identify its protein structure huntingtin has been transferred to the interna-
tional space station in an effort to take advantage of  extraterrestrial weightlessness con-
dition and microgravity crystallization techniques (NASA mission experiment CASIS 




by a proline rich domain which are located in the protein N terminus [3]. The presence 
of  similar homopolymeric glutamine and proline stretches in many transcription factors 
has lead scientists to the conclusion that huntingtin is also one such protein with similar 
functional properties [67-69]. Apart from its distinctive N-terminal structure the protein 
possesses several well described consensus motifs that are required for many protein-pro-
tein interactions – which is another characteristic of  Htt [70]. Such patterns, sequences 
or motifs include: a)  Huntingtin, elongation factor 3 (EF3), protein phosphatase 2A 
(PP2A), and the yeast kinase TOR1 - (HEAT) -  repeats [71] b) proteolytic cleavage sites 
that allow the fragmentation of  the protein through the function of  caspases 2,3,6 and 7 
[72,73] c) nuclear localization sequences [74] and d) posttranslational modification sites 
such as those for its phosphorylation and ubiquitination [75-78]. The wild type protein 
was initially considered to be found only in the cytoplasm and associated with the Golgi 
apparatus, the microtubules and the endoplasmic reticulum [79-81]. However, an early 
study by Hoogeveen et al. and later one by De Rooij et al. showed that huntingtin was 
also present in the nucleus [82,83]. This discovery further emphasized important protein 
roles such as transcriptional control, a role supported by the structural features and mo-
tifs that Htt possesses, like poluglutamine stretches and leucine zipper motifs. Huntingtin 
is also found in clathrin coated vesicles and it has been proposed that it interacts with 
proteins involved in cytoskeletal transport, receptor mediated endocytosis as well synap-
tic recycling [84,85]. Even though the highest huntingtin levels are found in the central 
nervous systems [86-88] the exact function of  the wild type protein is still not completely 
understood. Nonetheless early research in the field into the function of  the protein has 
shown that huntingtin is required during gastrulation in early embryogenesis and has a 
vital role in the functioning of  the basal ganglia and neuronal survival [89,90]. Addition-
ally, further studies have demonstrated that huntingtin may possess many further roles in 
many key cellular pathways. Several roles have been proposed for huntingtin: possessing 
an anti-apoptotic role and protecting from excitotoxicity [91,92], regulating the produc-
tion of  neurotrophic factors such as brain derived neurotrophic factor (BDNF)  [93,94], 
participating in or disrupting axonal transport and vesicle trafficking [95,96] and regulat-
ing synaptic function through partner proteins such as PSD-95 [97,98].
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1.2.2 Mutant huntingtin aggregates and inclusions
Soon after the discovery of  the HD causal mutation the presence of  neuronal aggregates 
and inclusions of  mutant huntingtin was also established as one of  the main disease 
pathological hallmarks. The designation of  the aggregates as  the main disease hallmark 
was made possible through a series of  successful experiments that used mouse and hu-
man studies to initially locate neuronal intranuclear inclusions and dystrophic neurites 
in HD brain [99] and later identify their role in toxicity, or protection therefrom, and 
in disease neurological phenotypes [100,101]. Even though the mechanisms through 
which Htt inclusions or Htt fragment inclusions lead to toxicity and neurodegeneration 
have not been completely elucidated. Some of  the  hypotheses advanced include inter-
ference and sequestration of  essential cellular proteins and transcription factors, prote-
asomal component interference and functional impairment [102,103], apoptosis [104], 
mitochondrial function damage [104,105] and alterations in cytoskeletal and synaptic 
function [106]. The factors that determine the capacity of  the mutant Htt to aggregate 
include the length of  the polyglutamine expansion and the length of  huntingtin poly-
glutamine fragments [107], the specific conformation of  the mutant protein as well as 
the sequences that flank the polyglutamine stretch such as the poly-proline motif  locat-
ed downstream of  the CAGs [108]. Miller et al. have suggested that the rate-limiting 
step for the formation of  inclusion bodies (nuclear or cytoplasmic aggregates) are the 
different conformational changes in monomeric Htt exon 1 fragments [109]. This sug-
gests that only modest reductions in the levels of  the mutant proteins or even their rela-
tive conformation ratios can have a profound effect in aggregate formation and toxicity 
[109,110]. Another significant factor correlated with the increased aggregate formation 
is the mutant protein proteolytic cleavage and the subsequent formation of  N-terminal 
fragments. Specifically, the function of  proteases such as caspase and calpain have been 
shown to increase the formation of  aggregates and neuronal susceptibility to cell death 
[111-113]. Independently of  all the above factors influencing aggregate formation, the 
propensity of  the mutant huntingtin to aggregate and cause disease pathology could 
additionally depend on chaperones [114,115], posttranslational modification enzymes 
[116,117] and can be influenced by the specific neuronal cell type properties and the mu-




neurons, astrocytes, oligodendrocytes and microglia [118-120].
1.2.3 Huntington’s disease brain pathology
Postmortem examinations of  HD carriers have shown that the brain tissue changes are 
mostly evident in advanced stages [121] and are characterized by tissue losses in the 
cerebral cortex and thalamus (reductions 21-29%) as well as the caudate and putamen 
(57% and 64% tissue loss respectively). Even though these large tissue losses are more 
visible in later disease stages, recent studies have shown that such brain atrophy and 
white matter disorganization events can even take place before the onset of  disease clin-
ical symptoms [122]. For example, medium spiny neurons make up to 95% of  the stri-
atal neuronal cell population and contain a plethora of  metabotropic, glutamate and 
dopamine receptors [123,124]. These receptors have been the subject of  intense research 
as to the possible mechanisms through which they can cause or contribute to neuronal 
cell death (see 1.3.4). In the majority of  HD cases the binding capacities of  these recep-
tors is reduced and this capacity reduction has been correlated to neuronal cell death 
[125,126]. Nonetheless it is not completely clear yet if  this receptor dysfunction leads 
to cell death or vice versa [126]. On the other hand, some cell types such as the striatal 
interneurons, the medium-sized calretinin-positive interneurons and the neuropeptide 
Y/somatostatin containing neurons are relatively spared, even in more advanced disease 
stages [127]. The reason that these cell types are less susceptible to the disease is not yet 
fully understood. It has been postulated however that this preservation can be related 
to the distribution of  the cells in the corresponding brain areas as well as their relative 
position to excitatory neuroreceptors responsible for cell over-excitation and subsequent 
cell death [128]. Finally, it has been shown that the cellular and neurochemical changes 
that take place in HD patient brains are accompanied by gliosis [129-131]. Gliosis is 
characterized as an increase in the population as well as the activation of  astrocytes, 
microglia and oligodendrocytes [128]. Microglial activation has been found widespread 
through the cortex, the pallidum and striatum and it has been even found to be present 
in pre-symptomatic carriers [132,133].
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1.2.4 Huntington’s disease peripheral pathology
Even though Huntington’s disease has been traditionally considered as a brain disorder it 
is characterized by additional peripheral symptoms such as weight loss and skeletal mus-
cle wasting, glucose intolerance, heart and gastrointestinal problems as well as testicular 
atrophy [134-138]. An increasing number of  studies points to the fact that these peripher-
al symptoms are not solely or even partially due to neurodegeneration of  brain cell struc-
tures and brain factors but are a result of  the mutant protein expression in the specific 
peripheral tissue cells and occur in parallel with the central nervous system [107,139]. 
Notably intracellular mutant protein inclusions as well as peripheral skeletal muscle cell 
dysfunction have been shown to be present even when the peripheral cell types are iso-
lated [140,141]. Weight loss is one of  the most common symptoms and especially in 
symptomatic HD individuals. Several studies have indicated that this weight loss is not 
only associated with nervous system damage but is also a result of  an increased meta-
bolic rate in these patients [142,143]. Moreover, it has also been shown that weight loss 
does not always follow symptom onset and a multifactorial system could govern the start 
of  weight changes in symptomatic and pre-symptomatic patients [136] Furthermore ac-
cording to a different study skeletal muscle wasting can also be attributed to expression 
of  the mutant huntingtin protein in the myocytes and a transition from slow-twitch to 
fast-twitch muscle fibers [144]. In addition, and using mouse models, it was shown that 
mutant huntingtin affects gene expression patterns in myocytes and that these expression 
changes are in parallel with early pathological and behavioral changes [144,145]. Other 
human as well as mouse studies have shown that HD mutation carriers are more likely 
to develop osteoporosis, diabetes, pancreatic dysfunction and impaired glucose tolerance 
[146-148]. Finally, the role of  the immune system has been the focus of  several studies 
and it has been shown that in HD blood is characterized by increased concentrations of  
proinflammatory and chemotactic cytokines such as interleukins 6 and 8, altered inflam-
matory signaling and a general overactivation [149-151]. This deregulation of  the im-
mune system has been attributed to expression of  the mutant Htt protein in the immune 
system cell types affecting cell signaling and cytokine release and migration [152]. Most 
importantly such an immune system over activation does not have an isolated cell type 




above such as muscle wasting and gene expression deregulation [153,154].
1.3 Huntington’s disease mechanisms of  cytotoxicity
Even though HD is a monogenic disorder the disease pathology is very multifaceted. 
The cytotoxic function of  the aggregated mutant Htt protein can exert its effect through 
a plethora of  processes as described above (see 1.2.2). In addition, it has been shown 
that mutant huntingtin cleavage products (especially N-terminal fragments) exacerbate 
the disease pathology. They are more toxic than full length huntingtin and increase the 
number of  intranuclear inclusions [55,155]. Huntingtin is proteolytically cleaved by 
caspases like caspase 3 and 6 and it has been shown that inhibiting caspase activity can 
reduce toxicity and aggregate formation (see 1.4.5). It has been proposed that increased 
caspase activation and substrate cleavage, caused in HD by intranuclear Htt accumu-
lation and release of  mitochondrial cytochrome c [156], can also be the cause behind 
phenotypic similarities across other neurodegenerative diseases such as Alzheimer’s dis-
ease [55,157,158].  In the following paragraphs, previously mentioned and additional 
mechanisms of  cytotoxicity are described in more detail.
1.3.1 Proteasomal deregulation
The ubiquitin-proteasomal system is one of  the main mechanisms of  cellular protein 
degradation in the nervous system and is involved in processes such as neuronal trans-
mission and neuronal plasticity [159]. In HD, it has been shown both in humans and an-
imal models that the mutant huntingtin protein is targeted for proteolysis but is resistant 
to its processing [99]. Studies that used HTT exon1 transfection polyglutamine aggre-
gates labelled with antibodies against parts of  the ubiquitin-proteasomal system demon-
strated co-localization with the protein inclusions as well as altered localization that 
could potentially adversely affect the proteasomal system function [160]. The reduced 
proteasomal ability to cleave the mutant protein as well as other polyglutamine proteins 
is attributed to the greatly expanded length of  glutamine repeats of  the mutant protein. 
As a result, these proteins are getting “stuck” in the 20S subunit of  the proteasome and 
do not allow for the subsequent entry of  the remaining catalytic substrates and other 
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proteins [161]. Additionally, using fluorescence recovery after photo-bleaching (FRAP) 
optical technology it was shown that the proteasome was irreversibly trapped within the 
N-terminal mutant huntingtin aggregates both in vivo and in vitro [162]. Even though 
the results of  the previous study did not exclude the possibility of  partial proteasome 
activity or Htt partial degradation – over time this delay in huntingtin or other substrate 
processing could have deleterious and adverse effects for cellular viability. Moreover, 
it should be noted that the results concerning the inability of  the proteasomal system 
to degrade the mutant expanded proteins are often contradictory. For example, and in 
contrast to previous studies, Rousseau et al. have suggested that the aggregation is not a 
result of  the main 20 S proteasomal subunit failure but rather of  19S regulatory particles 
(Rpt4/Rpt6) flanking the proteasomal catalytic core [163]. Additional data that further 
diffuse the role of  proteasomal dysfunction in HD have shown that it is only the fila-
mentous mutant Htt aggregates that have the potential to inhibit proteasomal function 
and not the formation of  inclusion bodies (IBs) [164]. Despite of  the opposing study 
results described above about the role of  proteasome in HD, this proteolytic complex 
constitutes a very interesting therapeutic target since even if  its function is shown not to 
be affected its activity may be targeted for additional stimulation and enhanced clearance 
of  the polyglutamine fragments [165]. 
1.3.2 Transcriptional deregulation 
The wild type huntingtin protein has also been shown to have a role in transcription 
regulation and to interact with many other transcription factors and regulatory pro-
teins[166]. On the other hand, during disease it has been confirmed that Htt mutant 
protein and protein fragment aggregates are involved in the sequestration of  proteins in-
volved in transcription, irregular subcellular localization of  CAG containing transcripts, 
alternative splicing; all events that lead to genome wide transcriptional deregulation in 
HD patients [167]. Specifically, it has been established that important cellular transcrip-
tion factors such as TATA binding protein, CBP, SP1 and p53 are recruited to these 
aggregates [168-170]. In two such studies it was shown that Sp1, a well-known wild type 
Htt interactor, exhibits reduced DNA binding (caused by mutant Htt) and that genes 




studies in human and animal models have shown that the functional types of  those genes 
whose expression is affected by mutant huntingtin include neuronal structure genes, sig-
naling receptors, axonal receptors and stress response genes [172,173]. In a recent study 
by Labadorf  et al. it was also shown that HD brain deregulated genes were enriched for 
immune response and neuroinflammatory genes as well as homeotic genes (Hox – Ho-
meobox genes) – a set of  genes that has not yet been widely investigated in the light of  
HD [174]. Furthermore, it has been suggested that these mRNA changes were not at-
tributable to cell loss only and exhibited a distinct disease related brain regional pattern, 
with gene expression similarities between those expressed in the HD caudate and the 
motor cortex [175]. Other important factors and regulators that have been implicated in 
HD transcriptional deregulation and whose function is influenced by the mutant protein 
include the neuronal factor transcriptional repressor REST [176], the peroxisome prolif-
erator-activated receptor gamma (PPARγ) [177] and the heat shock protein transcription 
regulator NF-Y [178].
Another major transcriptional mechanism disrupted in HD, which has potentially even 
greater influence than individual transcriptional factors deregulation, is chromatin re-
modeling. Chromatin remodeling is regulated by epigenetic processes such as histone 
posttranslational modifications and DNA methylation [179]. Studies from HD models 
have reported that mutant huntingtin also interferes with the function of  enzymes in-
volved in chromatin remodeling such as histone acetyltransferases, histone methyltrans-
ferase, ubiquitin ligases and transglutaminases [180]. Specifically, it has been shown that 
inhibition of  histone deacetylases by inhibitors such us sodium butyrate and phenylbu-
tyrate reversed the mutant protein related neurodegeneration [181,182]. Histone meth-
ylation is an epigenetic mechanism used to activate or repress transcription however it 
has been demonstrated that in HD histone methylation related proteins such as ERG-as-
sociated protein with SET domain (ESET) and its activator Sp1 are also deregulated in 
HD [183] Post-translational modifications as the ones performed by transglutaminases 
have also been shown to exhibit increased activity while their inhibition with cystamine 
in HD models ameliorated symptoms and increased the expression of  neuroprotective 
genes[184]. Much attention has been given lately to the role of  miRNAs in HD and their 
gene expression regulatory roles like for miR-9 and the neuronal gene expression RE1-Si-
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lencing Transcription Factor (REST) [185,186]. Finally, other ways in which chromatin 
remodeling is affected in HD and normal function of  the histone core proteins is disrupt-
ed are monoubiquitilation and post-translation modifications such as phosphorylation 
of  serine, threonine and tyrosine residues [172,187].
1.3.3 Mitochondrial activity and energy metabolism deregula-
tion
Mitochondria are well known regulators of  cellular health and are involved in cellular 
energy production, metabolism as well as apoptosis [188].  The mitochondria are an-
other cellular compartment that is thought to be disrupted in HD and eventually also 
contributing to neuronal cell death. A lot of  studies both in animal models and humans 
have described many different aspects of  mitochondrial dysfunction in HD. The differ-
ent mechanisms of  HD mitochondrial dysfunction can be briefly categorized into : a) 
mitochondrial membrane destabilization b) reduction of  the mobility of  the mitochon-
dria c) reactive oxygen species (ROS) overproduction with a concomitant Ca2+ cellular 
vulnerability through the deregulation of  the mitochondrial permeability pore [105]. 
More specifically, studies have shown that HD mitochondria exhibit increased CAG 
repeat length correlated membrane depolarization [189], reduced membrane potential 
requiring lower calcium depolarization loads [190] and reduced CA2+ loading capacity 
as well as evidence that CA2+ dependent pathways lead to oxidative phosphorylation 
impairment of  HD mitochondria  [191]. It has been demonstrated that full length mu-
tant Htt blocks mitochondrial movement and this effect correlates with increased mutant 
protein expression in the cytosol [192]. The same study showed that the mitochondria 
accumulated in areas of  aggregates while their trafficking was unchanged at neuronal 
areas that lacked aggregates. Reactive oxygen species, produced by the mitochondria 
during oxidative phosphorylation, have shown to be increased in HD. This has been 
attributed to the presence of  the mutant protein [193] and microglial over-activation 
which typically occurs after brain injury or immunological stimuli and has been shown 
to correlate with disease severity [194,195]. Moreover it has been shown that dysfunc-
tional mitochondrial metabolism in HD patients leads to diminished complex II, III and 




of  the metabolic regulator and transcriptional coactivator PGC-1alpha [197-199], as well 
as increased lactate production in the cortex and the basal ganglia [200,201]. Finally, the 
deregulation of  neurotransmitters such as dopamine and glutamate present at the stria-
tum and their disordered interactions with the mitochondrial system could also account 
for the preferential vulnerability of  these brain areas to the mutant Htt protein which 
involves but is not limited to processes such as the reduction of  cellular ATP stores, de-
regulation of  intracellular Ca2+ levels, increased synaptic dopamine levels and impaired 
glutamate uptake due to increased production of  ROS [202,203]. 
Despite the fact that so many studies have provided important clues about the deregu-
lation of  individual genes and complexes of  mitochondrial metabolism it is still unclear 
to what extend these mitochondrial defects have a causal effect in the disease or if  they 
are just the result of  long term disease toxicity [204]. Finally, for any one of  the afore-
mentioned genes or molecules to be targeted in therapeutic approaches e.g. to equilibrate 
their levels, their role in energetic pathways, and their interactors, have to be extensively 
investigated to avoid unwanted non-specific detrimental effects.
1.3.4 Synaptic dysfunction and excitotoxicity
Several studies have produced strong evidence that HD neuronal cells and especially 
those that make up the tissues that are first affected in the disease such as the striatum, 
are especially vulnerable to excitotoxic events and are characterized by aberrant synaptic 
and extra-synaptic functioning. HD model studies have shown that pre-symptomatic 
mice exhibit striatal dopamine signaling deficiencies and that dopamine receptor expres-
sion gradually declined with age, indicative of  the potential role of  the dopamine system 
in HD neuritic malformation and subsequent disease pathology [205,206]. The uptake 
of  another important neurotransmitter, glutamate, has been also shown to be reduced 
in the prefrontal cortex of  HD patients [207]. This reduction in glutamate uptake is 
usually also accompanied by a reduction in glutamate transporter 1 (GLT1/EAAT2) in 
corticostriatal regions [208,209]. The exact mechanism by which mutant huntingtin in-
terferes with synaptic functioning and the deregulation of  neurotransmitter levels is not 
fully understood yet. Nevertheless, HD model studies have shown that potential mecha-
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nisms could include the Htt mutant fragment transcriptional deregulation of  glutamate 
transporters that are mainly expressed by astrocytes that envelop synapses [210,211] 
and/or an inability to sustain the bioenergetics/glycolytic requirements for the proper 
functioning of  the enzymes responsible for glutamate uptake reactions (GLT-1, GAP-
DH). These enzymes in turn cause a neurotoxic release of  glutamate to the extracellular 
medium [212,213]. Finally, other complementary studies that have provided clues to 
the potential mechanisms involved in such excitotoxic cell death have reported that: 
a) full length mutant huntingtin disturbs neuronal Ca2+ signaling and makes medium 
spiny neurons sensitive to glutamate-induced apoptotic events [214] b) anti-apoptotic 
and pro-apoptotic proteins such as the cell death regulator Bcl-2 and the transcription 
factor p53 are selectively deregulated in striatal neurons and make these neurons more 
vulnerable to excitotoxic cell death [215] c) changes in the levels or removal of  BDNF 
or its tyrosine kinase receptor TrkB depletes the pro-survival signals that these molecules 
provide  and inhibits striatal cellular functionality [216] and d) reductions in endocanna-
binoids and mutant Htt mediated disruption of  their transcription which could in turn 
influence neurotransmitter release, synapse plasticity and the ability of  striatal cells to 
respond to excitotoxicity challenges [217-219].
1.3.5 Autophagy
Increasing evidence points to the fact that the wild type Htt has a vital and active role 
in autophagy and is involved in autophagosome transport and biogenesis processes 
[220,221]. For this reason, several important clinical autophagy modulation clinical tri-
als are under development that aim to enhance the ability of  selective or general auto-
phagic pathways to increase substrate recruitment, lysosomal activity and clear toxic 
proteins [222,223]. Autophagy is a cellular, protein clearance system that is divided into 
three main forms microautophagy, chaperone mediated autophagy and macroautoph-
agy [224]. This classification serves to describe the way the cargo is transported to the 
lysosomes, and degraded by hydrolases. In macroautophagy the mechanism of  toxic 
protein degradation involves autophagosome vesicle formation, its maturation and final-
ly its fusion with the lysosomes [225,226]. In HD, it has been reported that the macroau-




to a reduction in their turnover, an increase in their total number in HD cells and can 
also be linked to the increased levels of  protein aggregates and stored lipids [227].  Ad-
ditionally, an important regulator of  the macroautophagic process, the serine/threonine 
kinase mammalian target of  rapamycin (mTOR) has also been reported to be inhibited 
and this inhibition has been attributed to the presence of  the mutant Htt protein [228]. 
A separate study has also shown that the accumulation of  mutant Htt can also stimulate 
the endosomal-lysosomal system and this in turn can lead to autophagic cell death [229]. 
Studies also support the notion that the expanded protein loses its ability to reversibly 
bind to the endoplasmic reticulum, the Golgi complex, maintain the wild type protein 
cellular localization properties and regulate stress induced autophagy [230-232] all of  
which have been associated with neuronal dysfunction and neuronal cell death in HD 
[233]. In chaperone mediate autophagy (CMA) the substrates are selectively chosen for 
destruction and delivered to the lysosomal membrane [234]. This is in contrast to the 
macroautophagy process where whole areas of  the cytosol are engulfed and targeted 
to the lysosomes. In HD models, it has been shown that there is a compensatory regu-
latory mechanism where the CMA autophagic process activity is increased in response 
to a compromised macroautophagic pathway [235]. This increased activity is mediated 
through the upregulation of  lysosome-associated protein type 2 a (LAMP-2A) and ly-
sosomal HSC70 both of  which proteins have been shown to be directly involved in the 
clearance of  Htt [236]. However, with time the CMA autophagic pathway also gradually 
declines in its ability to compensate for the dysfunction of  the macroautophagic system 
and as a result there is a generalized failure of  autophagic clearance. In microautophagy 
the lysosomal membrane envaginates the material destined for destruction and inter-
nalized by the lysosomal lumen, however its molecular components are still not well 
understood in mammals [237,238].
1.4 Huntington’s disease therapeutic strategies
1.4.1 Transcriptional activity restoration strategies
One of  the potential methods to correct for the transcriptional deregulation observed in 
HD is through the inhibition of  histone deacetylase activity. Histone deacetylase inhib-
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itors such phenylbutyrate and sodium butyrate have been previously used in an attempt 
to improve transcriptional dysfunction by the relaxation of  DNA conformation, target 
HD specific pathological events such as caspase mediated cell death [239,240] or even 
improve HD phenotype through common neurological mechanisms such as improving 
neuronal BDNF trafficking [241]. In studies where histone deacetylase inhibition was 
used in HD models, it improved motor performance, appearance and body weight of  the 
mouse models. It has been shown that deacetylase inhibition also reverses mutant hun-
tingtin incited expression and causes a potentially beneficial change in the expression 
of  a specific set of  genes associated with the immune system and cell cycle – death, in 
the cerebellum, the cortex and the striatum of  HD mice [242]. Apart from the inhibi-
tion of  genome-wide transcriptional regulators such as histone deacetylate inhibitors, 
the transcriptional regulation of  individual genes important for the HD has also been 
suggested as an alternative approach. Examples of  such genes are the   cAMP response 
element-binding (CREB) and CREB co-activator CBP, brain-derived neurotrophic factor, 
REST as well as the zinc finger transcription factor SP1. CREB signaling function has 
been shown to be reduced in HD and several studies have attempted to increase CREB 
levels in an effort to improve neuronal survival [243]. Giampa et al. showed that in a rat 
HD model phosphodiesterase type 10 inhibition increased CREB levels in spiny neurons 
and provided a neuroprotective effect [244]. Finally, in order to control pathological 
transcriptional deregulation, several compounds that affect transcription have been used 
such as anthracycline antibiotics [245]. Stack et al. showed that anthracycline adminis-
tration in R6/2 HD mice improved nucleosome dynamics and the disease neurologi-
cal phenotype, shifting the balance between histone methylation and acetylation, while 
Ryu et al. demonstrated that mithracyclin suppressed SP1, SP3 related transcription in 
neurons through the suppression of  the ESET (H3-K9) histone methyltransferase and 
increased HD mouse model survival rates [246,247].
1.4.2 Mutant huntingtin lowering strategies
Silencing of  mutant huntingtin by RNA interference notably using siRNAs directed to-
wards the mutant mRNA has become one of  the most promising HD therapeutic trials 




the mutant Htt can be potentially reversed [249]. However, in this strategy it is important 
to prevent the silencing of  the wild type protein as well as other non–specific silencing 
events [250,251]. In this way, the beneficial effects of  silencing can be maximized and 
patient safety is ensured by avoiding toxic side-effects of  non-specific silencing, notably, 
of  wild type Htt that has been associated with perinatal lethality and motor and cogni-
tive defects in specific HD mouse models [252,253]. Even though the first attempts at si-
lencing the mutant protein were performed using RNA interference (RNAi) technologies 
[254] subsequent studies showed that delivery and efficacy could be improved through 
the use of  single stranded small inhibitory RNAs (siRNAs) and by using chemical modi-
fications and design improvements of  the administered molecules [255]. Moreover, addi-
tional experiments that have also shown great promise have been targeting the silencing 
of  the mutant protein through the use of  antisense oligonucleotides (AONs). The main 
difference between AONs and RNAi is that while AONs are delivered as single strand 
molecules RNAis are delivered as delivered as duplexes. Furthermore, RNAis are con-
sequently engaged by the Argonaute protein family as the catalytic components of  the 
RNA-induced silencing complex (RISC) lead only one of  the two strands to eventually 
bind the complementary RNA [256]. Even though RNAi and AONs recognize their 
targets through Watson and Crick base pairing rules additional key differences that sep-
arate the two technologies are that compared to AONs RNAi works through a well-de-
fined RNA degradative pathway (Drosha/Dicer), their targeting efficiency towards the 
mutant protein, the delivery efficiency to the targeted tissue and their half-life within 
the administered tissue cells [257,258]. Furthermore, since the silencing of  wild type 
huntingtin function is undesirable due to its vital function in a plethora of  cellular, neu-
rological and neurodevelopmental processes [259] a lot of  effort has been put into the 
allele selective silencing of  the mutant protein, something that can be done through the 
targeting of  single nucleotide polymorphisms [260,261]. Since the first silencing studies 
in which a significant reduction of  mHtt was achieved through the administration of  
siRNA and anti-Htt constructs [262,263] a lot of   preclinical  HD model, Htt lowering 
studies have already been performed [264]. Some of  the most recent, promising studies 
include those that incorporate the administration of  cholesterol-conjugated Htt-siRNA 
in mice in order to increase tissue  uptake [265], the allele specific knockdown of  mHtt 
with S-constrained-ethyl (cET) motif  AONs [266] and the AONs RNase-H-mediated 
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degradation of  huntingtin through administration in HD mice cerebrospinal fluid [267]. 
1.4.3 Mutant huntingtin clearance and anti-aggregation strat-
egies
In order to address the issue of  the expanded mutant huntingtin resulting to a toxic gain 
of  function a potential therapeutic strategy has been to identify modulators that possess 
anti-aggregational roles and that can lead to mutant protein aggregation and inclusion 
body reduction. A good example of  experiments that attempt to reduce the accumulation 
of  aggregated mutant proteins is through the use of  chaperone protein member families. 
Chaperone proteins such as HSP40 and HSP70 have been known to promote refolding 
and degradation of  misfolded proteins [268,269]. In a similar approach Labbadia and 
colleagues showed that induction of  the heat shock response (HSR) via the heat shock 
factor 1 transcription factor (HSF1) and inhibition of  chaperone HSP90 improved HD 
related phenotypes in the R6/2 mouse model [270]. A subsequent study from the same 
group and in HD transgenic mouse crossbreeds overexpressing the neuronal chaper-
one HSJ1a (DNAJB2a) reduced mutant huntingtin aggregation and enhanced solubility 
[271]. Nonetheless, some of  the above ameliorative effects, of  the activation and overex-
pression of  the chaperone machinery, have been transient and it has been suggested that 
synergistic combination therapies might be required for these therapeutic strategies to be 
more effective [272]. 
Other anti-aggregation approaches include those that use the administration of  vari-
ous, nontoxic, soluble disaccharides that act to stabilize the partially unfolded mutant 
huntingtin and prevent disease inclusion formation. One such compound, trehalose has 
been used in HD as well as other polyglutamine and neurodegenerative disease models 
and has shown to prevent neurodegeneration, enhance autophagy and alleviate disease 
mediated pathology [273-275]. Finally, much evidence suggests that cellular huntingtin 
clearance through induction of  autophagy can also provide therapeutic benefits [276-
279]. Apart from potential small molecule regulators of  autophagy like trehalose and 
as described above, other approaches to regulate autophagic degradation of  mutant 




phorylation of  specific N-terminal serine residues [280,281] or acetylation of  lysine 444 
(K444) [282] b) autophagy induction through mTOR inhibition with rapamycin [283] or 
other mTOR dependent pathways and molecules [284,285] c) through other mTOR in-
dependent autophagy inducers such as L-type Ca2+ channel antagonists, K+ATP chan-
nel openers and other pharmacophores [286-288] .
1.4.4 Mitochondrial and synaptic function restoration strate-
gies
Since mutant huntingtin has been shown to interfere with mitochondrial energy produc-
tion and metabolism [289,290] it has been hypothesized that the administration of  com-
pounds and molecules that could replenish the energy cellular banks and improve the 
energy deficient profile in patients may also represent a likely therapeutic pathway. One 
of  the molecules that has been proposed to have the potential to rectify the energy deficit 
in HD patients is creatine [291]. Creatine is synthesized in the kidney and the liver, taken 
up by tissues such as brain, heart and the skeletal muscle through a sodium dependent 
transporter [292] and together with phosphocreatine serve as short term energy banks 
when energetic demands rapidly increase [293]. Creatine has been shown to improve 
motor performance and reduce brain atrophy as well reverse mitochondrial dysfunction 
in transgenic mouse models of  HD [294,295]. Additionally, a 16-week clinical trial of  
creatine administration showed that creatine was well tolerated and reduced oxidative 
stress levels in HD patients [296]. However even though creatine was also shown in a 
subsequent study [297] to improve cortical thinning, other aspects of  the disease such 
as cognition were not affected. Therefore, considering the potential side effects of  long 
term creatine administration, especially in presymptomatic individuals, further studies 
will be required to prove the applicability of  this compound in HD. Another correspond-
ing molecule, with neuroprotective and antioxidant properties, is the electron transport 
chain cofactor coenzyme q10 (CoQ10) which is involved in aerobic respiration and ATP 
energy production. CoQ10 has in some cases been combined with creatine administra-
tion to provide additional neuroprotection in HD as well as Parkinson’s disease mouse 
models [298]. Multiple HD transgenic mouse models have demonstrated the neuropro-
tective properties of  CoQ10 and shown that it can protect dopaminergic neurons, reduce 
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mitochondrial toxins as well as improve mouse model rotarod performance in combina-
torial, preclinical trials [299,300]. It should be noted however that the results of  clinical 
studies of  coenzyme Q10 [301] have not been so promising as HD mouse model studies 
and considering the low treatment benefit compared to patient effort and energy require-
ment, further clinical trials of  this molecule have been currently halted.
Along with mitochondrial restoration strategies much attention has been given to the 
restoration of  cortico-striatal synaptic function in an effort to prevent selective vulnera-
bility and neurodegeneration. The restoration of  synaptic function has been the aim of  
many preclinical and clinical trials to regulate the release of  neurotransmitters such as 
dopamine and glutamate, the functioning of  neuroreceptors such as the N-methyl-D-as-
partate receptor (NMDAR) and the expression levels and the release of  neuromodula-
tors and growth factors such as the endocannabinoids and brain derived neurotrophic 
factor [302]. In particular, experiments on transgenic R6/2 mouse models showed that 
dampening of  the aberrant glutamate uptake by activation of  metabotropic glutamate 
auto-receptors, resulted in increased model survival and a significant rescue in striatal 
and cortical neuronal loss [303]. Another attempt to prevent striatal loss and atrophy in 
HD as well as other neurodegenerative diseases has been through the overexpression of  
BDNF [304]. In HD, it has been shown that the increase of  BDNF levels in YAC128 
mouse models has resulted in the normalization of  dopamine D2 receptor expression 
while striatal cell loss and motor dysfunction have also been reduced [305]. Finally, ad-
ditional synaptic rescue schemes include the modulation of  synaptic transmission via 
endocannabinoid signaling [306,307] and administration of  neurotransmission inhib-
itory drugs as riluzole, memantine and the dopamine pathway inhibitor tetrabenzine 
[308-311].
1.4.5 Other strategies
Cell replacement therapy is another favorable approach that can potentially delay disease 
progression by replenishing the cells that have been lost due to the pathological effects 
of  the mutant Htt protein. To date, cell therapy approaches have been through the use 




showed that the implantation of  human neural stem cells in the R6/2 mouse model had 
suboptimal results due to low cell survival and differentiation. However, a different study 
by Rossignol et al. showed that co-transplantation of  adult mesenchymal and neural 
stem cells in a transgenic rat model prolongs the survival of  the neural stem cells and cre-
ates a more favorable transplantation microenvironment [313,314]. Transplantation of  
fetal striatal grafting has also been shown to improve the motor as well as the cognitive 
decline of  HD patients. Nonetheless the grafts exhibited poor survival over time and con-
versely the grafting beneficial effects diminishing over time [315,316]. The poor survival 
of  the grafts in the host has been attributed to poor vascularization. Trophic support can 
potentially be improved as grafting techniques and protocols are continuously improved 
[317,318]. Nevertheless, achieving the delicate balance of  the type of  stem cells to use 
(MSCs or iPSCs), during which HD disease stage (early, middle or late) and the specific 
neurodegeneration events these cells will target, are the greatest challenges of  future 
stem cell trials and the determinant success factor for this therapeutic method [152].
To conclude the list of  therapeutic approaches it has been suggested that targeting 
caspase dependent cleavage events is another prospective approach for the prevention of  
neuropathological features in HD and other neurodegenerative disorders [319]. Accord-
ing to the “toxic fragment hypothesis” the presence of  multiple proteolytic sites on the 
Htt protein, in combination with the aberrant activity of  proteases such as caspases and 
calpains may lead to numerous, variable length polyglutamine containing peptides that 
can be toxic. The identification of  the specific combinations of  enzymes and sites caus-
ing the most toxic peptides has been the focus of  several research groups. Using YAC 
HD mouse models it has been shown that mice expressing mutant huntingtin resistant to 
caspase 6 cleavage, were protected against neurotoxic events and did not develop striatal 
neurodegeneration [320]. For this purpose, drugs like minocycline have been used in pre-
clinical trials and in an attempt to inhibit the production of  huntingtin toxic fragments by 
caspase cleavage [321,322]. Furthermore, initial clinical trials of  minocycline use have 
exhibited stabilization of  motor function and a significant amelioration of  psychiatric 
symptoms in HD patients [323]. Even though the role of  caspases is still not completely 
understood and the experimental results are not always consistent with the initial re-
sults from the caspase 6 resistant YAC mice [324], new molecules are constantly being 
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developed against caspase-6 aiming to increase the therapeutic potential of  this method 
[325,326]. Yet increasing evidence points at important non-apoptotic roles of  caspases 
such as caspase-6. Furthermore, alternative, complementary proteolytic pathways exist, 
which continue to give rise to the HD proteolytic toxic peptides (even after ablation or 
downregulation of  caspase-6 function). This means that research in this direction should 
proceed with caution as to the molecules used and the extent to which the function of  
these proteases can and should be modified.
1.5  Biomarkers
1.5.1 What is a biomarker?
A  biomarker is a physiological, molecular, biochemical or pharmacological measure-
ment that can be obtained from the body of  a patient and that can provide a good in-
dication of  disease prediction/progression or treatment efficacy in that patient [327]. 
Additionally, and according to the US Food and Drug administration (FDA) pharma-
cogenomics guidance ( http://www.fda.gov/drugs ) a biomarker should be measured 
in an analytical test system with clearly established performance characteristics and for 
which there is an established scientific framework that elucidates the significance of  the 
biomarker test results. A good biomarker should also have the following properties: a) be 
able to detect disease features with high sensitivity (able to detect the condition when it 
is present) and high specificity (able to rule out a condition when it is absent), especially 
when compared to diseases with similar phenotypes  and b) be easily, reliably and ro-
bustly detected, preferably in an easily collectable tissue (such as peripheral blood) and 
with minimum distress to the patient [328]. Finally, a good biomarker is judged by its 
positive predictive power (proportion of  patients with a correct positive diagnosis over 
the total number of  individuals who have been called to have the disease, true and false) 
and its negative predictive value (proportion of  patients with a negative test and a correct 
diagnosis over the total number of  people that have been called to not have the disease, 
including the false negatives).




biomarkers can be classified into: a) biomarkers which predict patient survival (prognos-
tic), b) biomarkers which follow disease progression (monitoring biomarkers), c) bio-
markers which can be used to evaluate drug safety and efficacy (pharmacodynamic), d) 
biomarkers which identify individuals likely to benefit from a treatment (predictive) and 
e) biomarkers which can predict the outcome given the response to therapy (surrogate 
biomarkers– see Figure 1)  [329]. Prognostic and diagnostic biomarkers are grouped 
together and are otherwise called type 0 category biomarkers while therapeutic and sur-
rogate biomarkers have been defined as type 1 and type 2 biomarkers respectively [330]. 
A prognostic biomarker can provide information about the outcome of  the disease in 
Figure.1 Biomarker type classification based on: a) the molecular subclass from which the iden-
tified biomarker originates b) biomarker tissue relative to disease central pathology tissue and 
c) biomarker provided information relative to disease risk (diagnostic), disease progression (prog-
nostic), therapeutic potential (predictive) and safety or effectiveness of  therapeutic approach.
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specific population groups however it cannot provide information about the patient’s 
response to a treatment such as those provided by predictive biomarkers. On the other 
hand, pharmacodynamic markers can provide information about how well the treat-
ment works (proof  of  principle) or can be used to optimize the dose of  the administered 
treatment. Surrogate biomarkers are measurements that can potentially replace clinical 
endpoints and this is performed in a less labor intensive or expensive way than the stan-
dard and established clinical endpoint measurements methods for the specific disease. A 
biomarker can be an intrinsic measurement such as those provided by brain or other tis-
sue imaging techniques, biomolecular and fluid sample tests or they can also be extrinsic. 
For example, an extrinsic surrogate biomarker can be cigarette smoking to the clinical 
end point of  lung cancer. Moreover, biomarkers can be divided to the level to which 
they take place in a disease (molecule, cell etc.) or even according to their relationship 
to disease pathology (primary or secondary pathology) [331]. A good biomarker should 
also undergo validation and qualification [332]. Validation refers to the evaluation of  the 
biomarker’s sensitivity, specificity and reproducibility while on the other hand biomark-
er qualification refers to acquisition of  the evidence linking a biomarker to a specific clin-
ical endpoint [333]. Even though a biomarker can be linked, validated and qualified to 
a clinical endpoint (surrogate biomarker) this may not always be associated with disease 
causality [334]. Specifically, such a biomarker may be associated with the clinical end-
point but could nonetheless have nothing to do with the disease tissue pathology or the 
molecular pathways that lead to the disease specific endpoint. Such a biomarker could 
for example be a measurement in the peripheral blood of  neurodegenerative disease pa-
tients not correlated to brain degeneration and its associated molecular pathways and yet 
correlated to specific disease endpoints. Finally, it should be emphasized that apart from 
the disease specific, drug and disease endpoint biomarker relationships, vital properties 
of  a biomarker should be the detailed reporting of  laboratory, experimental, clinical and 
statistical information that will allow for the unambiguous replication and reconstitution 
of  the initial biomarker study results [330,335]. 
1.5.2 Biomarkers in Huntington’s disease - needs and challenges




markers are needed for HD as diagnosis is done by the genetic identification of  the num-
ber of  CAG repeats. Thus, HD biomarker development is focusing on the areas of  phar-
macodynamics, therapeutic monitoring and disease progression diagnosis. Additionally, 
the ability to identify potential HD mutation carriers provides a period of  several years 
to decades that can be used for presymptomatic therapeutic intervention. This is further 
emphasized by the fact that even though individuals exhibit no distinct phenotypic fea-
tures during this preclinical, presymptomatic disease stage, subtle subclinical molecular 
and neurodegenerative events are already taking place [336-339]. Another reason that 
identification of  good biomarkers is a top priority for HD research is the recent develop-
ment of  many potential treatments and therapeutic molecules (see 1.4). These therapeu-
tic strategies have been partially validated with the help of  various HD models. However, 
unless effective and standardized biomarkers have been described it will be very difficult 
to objectively describe any ameliorative outcomes of  potential treatments when patients 
progress to the clinical trial stages. Such biomarkers should ideally describe the disease 
progression or even the pathology reversal equally well in early and presymptomatic pa-
tients, considering that these patients would benefit the most from therapeutic interven-
tion. Nevertheless, even though high standards are required for the discovery of  sensitive 
biomarkers, the multiplicity of  pathological features in HD dictate that more than one 
type of  biomarkers will be required to accurately describe the disease progression and 
the clinical trial benefits. Such a panel of  biomarkers would be taking advantage of  clin-
ical progression tests, technological developments in imaging technologies and refine-
ment of  biochemical markers already under development. For Huntington’s disease as 
well as other neuropsychiatric disorders, one of  the main problems in studying the actual 
disease pathology is that it is hardly possible to collect tissue samples from brain areas of  
interest or obtain representative patient sample numbers to achieve the desired statistical 
power for a conclusive result [340,341]. Additionally, postmortem samples, which are 
sometimes also used to study the disease, are usually of  suboptimal quality, either due 
to postmortem delay or due to pathological events affecting the tissue for several years, 
like in Huntington’s disease [342-344]. Finally, development of  qualified (see 1.5.1) and 
informative pharmacodynamic, monitoring and surrogate biomarkers will not only aid 
in the development of  clinical trials and therapeutic agents but also assist researchers to 
get a better understanding of  the disease pathology itself.
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1.5.3 Blood based biomarkers for Huntington’s disease
As described above HD patients are often irritable and exhibit choreatic symptoms and 
psychiatric disturbances (see 1.1.3/1.1.4). This makes it even more challenging to per-
form biopsies and secondary pathology tissue samplings and examinations in symptom-
atic patients. At the same time the ease with which peripheral blood can be collected 
repeatedly over a period of  time, makes it a very attractive tissue for use in preclini-
cal, clinical and biomarker discovery studies. Furthermore, huntingtin is also expressed 
in blood and, as such, surrogate biomarker changes could be identified in blood inde-
pendently of  potential causality to central disease pathology. The changes found in blood 
could reflect the effect of  the mutant huntingtin itself  within the tissue or secondary 
pathological events from other tissues, such as muscle. For example, it has been suggest-
ed that in neurodegenerative diseases the blood-brain barrier might be compromised, 
potentially exacerbating of  brain pathology and causing leakage of  proteins or other 
molecules [345]. Finally, profiling of  gene expression in HD patients has shown that in 
whole blood and caudate samples transcription of  large genomic regions is regulated in 
a synchronized fashion [346]. However, independently of  the pathological mechanisms 
or other events traced by blood biomarkers they will need to be robustly associated with 
well-established HD clinical endpoints.
Blood consists mainly of  plasma (55%), red blood cells (45%) and leukocytes and plate-
lets (last two together ~ 1%). Most blood HD studies have been performed either using 
plasma and serum to examine the free proteins and molecules in these liquids; or using 
the leukocytes to examine cellular organization and disease related processes. The blood 
component or molecule under examination is often chosen based on the suspected de-
regulated disease pathway. By following one such hypothesis-driven approach and to 
study oxidative damage and dysfunction of  the mitochondria in HD, serum levels of  
8-hydroxy-2'-deoxyguanosine (8OH2'dG), an oxidative DNA damage indicator, have 
been investigated [296,347,348]. Its levels have been reported to be elevated in HD and 
other neurodegenerative diseases and HD mouse models overexpressing a hydrolase 
that break it down have conferred a protection against HD-like symptoms [349,350]. 




individuals before and after CoQ10 treatment [347] (for role of  Coq10 in HD see 1.4.4). 
Nevertheless, the results have not always been consistent with the initial positive findings 
and it has been proposed that 8-hydroxy-2'-deoxyguanosine has only limited potential at 
assessing clinical disease features [351-353]. A more direct approach of  disease specific 
biomarker identification involves the measurement of  the mutant huntingtin itself  in 
circulating T cells, B cells and monocytes [354,355]. The results of  the study performed 
by Weiss et al. showed that mHtt leucocyte levels were lower in presymptomatic pa-
tients when compared to symptomatic and were also associated with disease burden and 
caudate atrophy scores. The quantification of  mHtt itself  as a biomarker obtained from 
peripheral readings such as blood or other peripheral fluids such as cerebrospinal fluid 
(CSF) can be very important since it can identify the effect of  mutant protein lowering 
therapeutic strategies (pharmacodynamic) (see 1.4.2) ; can be indicative or associated 
with peripheral inflammation and immune system deregulations (see 1.2.4) (monitor-
ing – predictive biomarker properties); and it can provide mechanistic links and clues to 
disease pathology. For example, the latter can be achieved by measuring mutant protein 
relationships in blood and other peripheral tissues, such as the relationship of  soluble 
and aggregated mutant huntingtin levels [356]. Since it is not yet clear to which extent 
the interplay between aggregated and soluble mutant proteins forms influences neuronal 
cellular toxicity, the delineation of  the relative amounts of  the above two species or con-
formers can provide additional clues to the disease pathology and constitute on its own 
a type of  biomarker. Other individual molecule and compound findings that have been 
described in HD blood include increased cytokine levels (mainly IL-6, IL-8 and TNF-a), 
kynurenine : tryptophan ratios as markers of  microglial activation and persistent inflam-
mation [357,358] and  lower levels of  BDNF, which is associated with striatal neuron 
survival signals, in HD patients serum and it association with longer CAG repeats [359]. 
Apart from specific hypothesis driven approaches, as illustrated above, peripheral blood 
has also been used in non-hypothesis driven efforts to identify peripheral biomarkers. Such 
non-hypothesis driven methodologies take advantage of  state of  the art high-throughput 
techniques such as mass spectrometry and genome wide gene expression profiling plat-
forms to identify additional peripheral molecular biomarkers, among others metabolites 
and mRNAs [360,361]. To identify changes in mRNA expression levels in HD scientists 
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have mainly used whole peripheral blood and isolated leukocyte samples of  patients as 
well as animal models [362-366]. Even though the overlap between studies result has not 
been very good for the mRNA changes identified, the per study findings have demon-
strated that blood holds potential in being used as a source for disease progression and 
therapeutic efficacy. For example, Hu et.al. have demonstrated that dynamic regulator 
of  chromatin plasticity H2A histone family (H2AFY) is overexpressed both in the blood 
and frontal cortex of  HD patients, that this association precedes clinical symptoms and 
that the levels of  this marker respond to a neurodegeneration suppressor, thus imply-
ing pharmacodynamic potential [364]. The above biomarker also contains many of  the 
properties of  an ideal biomarkers as it is validated in HD mouse models, changing ac-
cording to disease severity and found early in the disease allowing for a wider therapeutic 
intervention window. Moreover, it has a known mechanism in disease pathology i.e. 
chromatin regulation (for the role of  chromatin regulation in HD see 1.3.2) [367,368]. 
Apart from gene expression platforms metabolomics and proteomics technologies have 
been widely used to also identify such biomarkers in HD blood. Notably metabolom-
ics could be a promising approach as deregulation of  metabolism is a known HD pa-
thology. Metabolomics and proteomics studies have also provided much information 
about the changes in patient blood samples [141,369-371]. For instance, proteomic and 
metabolomic changes in HD blood include altered levels of  brain derived metabolites 
such as 24S-hydroxycholesterol in pre-manifest carriers, associated with metabolically 
active neuronal cells [372]; the presence of  a catabolic phenotype in early HD patients, 
associated with aliphatic amino acids and changes in fatty acid breakdown markers like 
glycerol and malonate [373] and identification of  neuroinflammation activation proteins 
in plasma [138]. Together all of  the above results show that blood has great potential to 
provide prodromal, monitoring as well as pharmacodynamic HD biomarkers.
1.5.4 State of  Huntington’s disease clinical and imaging bio-
markers
The identification of  clinical biomarkers involves a series of  tests and examinations 
that have the purpose of  measuring cognitive and neuropsychiatric condition and mo-




and the standard method of  assessment of  clinical disease progression is the Unified 
Huntington’s Disease Rating Scale (UHDRS) [374]. This score comprises of  different 
sub-scores that assess the patient’s motor performance with tests such as oculomotor 
and finger tapping performance, tongue control and force, grip and posture control but 
also tests assessing their cognitive and functional condition. The advantages of  such 
clinical measures are that they are usually inexpensive, standardized, relative quick and 
noninvasive. On the other hand, the disadvantages are that they are subjective and dis-
play inter and intra-rater variability [375]. However, despite potential disadvantages of  
some clinical markers there have been organized efforts such as the TRACK-HD and 
PREDICT-HD consortia that aim to improve the objectivity of  these clinical measures 
as well as providing higher longitudinal change sensitivity and cross sectional differ-
ences in presymptomatic patients [376-380]. For example, 36-month observational data 
from the TRACK-HD study showed that several quantitative motor and cognitive tasks 
showed increased rates of  decline. Furthermore, psychiatric markers such as apathy also 
exhibited significant increases [379] while the PREDICT-HD study reported that symp-
toms such as depression, anxiety and obsessive-compulsiveness were present more in 
HD mutation carriers [381].
A group of  HD biomarkers that have produced some of  the most significant results 
during the last years have been collected with the help of  (neuro)imaging technologies. 
These technologies have the ability to describe brain loss changes as well as brain mor-
phological changes in HD mutation carriers. The advantages of  imaging techniques are 
that they non-invasive and that the data produced are in general well reproducible [382]. 
On the other hand, imaging techniques are usually quite expensive, especially when com-
pared to clinical scoring systems. An additional disadvantage is that these examinations 
are sometimes difficult to perform due to the structural design of  the imagers and the 
fact they can cause claustrophobia or are even unsuitable for patients that exhibit highly 
choreatic movements  [376]. One of  the most used of  these technologies is magnetic 
resonance imaging. MRI studies have demonstrated how cortical degeneration is related 
to the clinical symptoms and how the cortical changes develop in different patients. One 
such prominent study by Rosas et al. showed that in HD subjects thinning of  the cor-
tical ribbons takes place from the posterior to anterior regions, that these changes take 
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place early in the disease and could be accountable for the disease heterogeneity [383]. 
In a subsequent study these patterns of  cortical thinning were associated with different 
motor phenotypes, while functional and cognitive scores were closely related to specific 
cortical areas [384]. Other promising imaging techniques include functional MRI, PET, 
diffusor tensor imaging and magnetic resonance spectroscopy. These techniques can of-
fer information about brain area dynamic changes, functional interconnectivity and mi-
crostructural degeneration [385,386]. Notably data from the IMAGE-HD study, using 
quantitative susceptibility mapping and multimodal magnetic resonance imaging, has 
shown that presymptomatic patient brain areas exhibited a higher iron content and that 
caudate volume loss could separate presymptomatic HD mutation carriers from controls 
respectively [387,388]. When it becomes possible to combine complementary informa-
tion from different imaging types in longitudinal studies, this will greatly improve the 
potential and the sensitivity of  imaging as a biomarker source. However, such an effort 
is not a small task and it will require greater standardization as well as the integration 
of  different classes of  professionals such as doctors, clinical researchers and statisticians 
[389].
1.5.5 Other molecular and biochemical fluid biomarkers
Aside from blood and the relative advantages it offers compared to other tissues, cerebro-
spinal fluid (CSF), muscle, saliva and urine have also provided useful and informative 
“wet” biomarkers for HD. The use of  CSF is becoming increasingly popular in monitor-
ing disease progression in other major neurodegenerative disorders such as Alzheimer’s 
disease and Parkinson’s disease [369,390-392]. CSF advantages include the fact that it is 
also relatively accessible and that it interacts with central nervous system tissues and is 
“open” to brain derived proteins which can potentially mirror the pathological changes 
in the brain tissue. Wild et al. were able to reliably quantify mHtt at femtomolar sensi-
tivity in mutation carriers’ CSF and also showed that higher mHtt load was correlated 
to reduced cognitive function and increased motor dysfunction in HD patients [393]. 
In a separate study, Tan et al. used postmortem samples to show that CSF possesses an 
mHtt and tissue specific property called cell-based aggregation (CBA) seeding, that seeds 




thology and can also act as a potential molecular biomarker for HD [394].  This CSF ag-
gregate seeding propensity could be used to track disease progression (i.e. constituting a 
monitoring biomarker) by measuring CBA activity in a cell based assay. Saliva is another 
tissue that has been used to identify disease biomarkers, notably to study neuroendocrine 
regulation disturbances such as the hypothalamic-pituitary-adrenal (HPA) axis hyperac-
tivity and depression found in HD carriers. Cortisol concentrations obtained from HD 
mutation carriers’ saliva samples were increased, indicative of  HPA axis dysfunction 
and also exhibited a correlation with motor and functional scores [395]. It should be not-
ed however that the association of  HPA axis activity with HD disease stages (pre-symp-
tomatic vs (motor)symptomatic) and psychiatric symptoms (depression, suicidality) is 
not yet clear and further longitudinal studies are required for such saliva measurements 
to constitute potential biomarkers [396,397]. Additional examples of  the use of  other ac-
cessible fluids and tissues in biomarker identification include the reports of  progressively 
increased cortisol levels in patient urine samples [398], the reduction of  muscle contrac-
tility markers and a switch from fast to slow twitch muscle types in skeletal muscle of  
patients [399]. Finally, the function of  the autonomic nervous system (ANS) in Hunting-
ton’s disease has also been investigated to explore how this is affected in patients [400]. 
When standardized ANS system tests (sympathetic skin responses, blood pressure, heart 
rate variability etc.) were performed in patients, autonomic symptoms were found to be 
related to HD functional disability and depression and autonomic deregulation correlat-
ed with central nervous system degeneration tests and scores, such as the symbol digit 
modalities test and the UHDRS motor score [401,402]. These results support the notion 
that autonomic functional assessment could present a complementary non-invasive mea-
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Transcriptome analysis is of  great interest in clinical research, where significant differ-
ences between individuals can be translated into biomarkers of  disease. Although next 
generation sequencing provides robust, comparable and highly informative expression 
profiling data, with several million of  tags per blood sample, reticulocyte globin tran-
scripts can constitute up to 76% of  total mRNA compromising the detection of  low 
abundant transcripts. We have removed globin transcripts from 6 human whole blood 
RNA samples with a human globin reduction kit and compared them with the same 
non-reduced samples using deep Serial Analysis of  Gene Expression. 
Results
Globin tags comprised 52-76% of  total tags in our samples. Out of  21,633 genes only 
87 genes were detected at significantly lower levels in the globin reduced samples. In 
contrast, 11,338 genes were detected at significantly higher levels in the globin reduced 
samples. Removing globin transcripts allowed us to also identify 2112 genes that could 
not be detected in the non-globin reduced samples, with roles in cell surface receptor 
signal transduction, G-protein coupled receptor protein signalling pathways and neuro-
logical processes.
Conclusions
The reduction of  globin transcripts in whole blood samples constitutes a reproduc-








Transcriptomics technologies have successfully been used for biomarker discovery and 
the study of  physiological and pathophysiological mechanisms [1]. Recently, advanc-
es in sequencing technology have allowed for direct identification of  transcript specif-
ic sequences (tags) that are digitally counted, and the analysis of  differences in gene 
expression with unprecedented accuracy [2]. One specific application of  next genera-
tion gene expression analysis is DeepSAGE, a tag sequencing method on the Illumi-
na high-throughput sequencing platform that is analogous to LongSAGE [3]. Such 
sequencing-based technologies offer distinct advantages over expression micro-arrays, 
such as a higher dynamic range, the increased power for detection of  low abundance 
transcripts, and the detection of  novel transcripts and transcript variants [4,5]. Further-
more, next generation sequencing technologies show less variation between different 
study sites than microarray technology and are not content-limited [6]. 
Transcriptome analysis of  peripheral blood is of  great interest for clinical research; where 
significant differences between samples obtained in a minimally invasive and cost-effec-
tive manner can be translated into gene signatures of  disease stage, drug response and 
toxicity [7]. Blood comes into contact with almost every tissue and organ of  the human 
body and due to its cellular composition it can reflect both physiological and pathogenic 
stimuli. Gene expression differences in peripheral whole blood have been used to deter-
mine signatures related to acute myeloid leukaemia [8] , but also in neuropsychiatric dis-
orders and Huntington’s disease where significant correlation was found between blood 
and brain gene expression [9,10]. Furthermore disease signatures can be robust across 
tissues and experiments and in a large meta-analysis study performed by Dudley and 
colleagues, it was demonstrated that gene expression profiles in various tissues from the 
same disease were more similar than gene expression profiles from identical tissues from 
different diseases [11]. Furthermore, 80% of  genes expressed in peripheral blood cells 
are shared with other important tissues [12]. These results suggest that transcriptome 
analysis of  the blood is often informative even when the originating pathology stems 
from a different tissue.
Chapter 2             
82
Blood is composed of  three main cell types. The main component is red blood cells 
(95%), including the progenitor erythrocytes called reticulocytes, followed by platelets 
(5%) and white blood cells (<1%). While white blood cells make up the minority, they 
are the most informative and in the past, many studies have been performed on the 
isolated white blood cell fraction. However, white blood cell isolation kits can induce 
a technical bias that can confound the original expression profile of  the samples and 
delayed sample processing can affect gene expression profiles [13,14]. This means that 
white blood cell separation protocols require quick and accurate processing, which can 
be difficult in a clinical setting. The expression profile of  a sample is better preserved 
by a whole blood collection method, like the PAX gene blood RNA system [15]. An-
other advantage of  this system is that samples can be frozen for up to 2 years without 
affecting the expression profile [16]. However, cell sorting and counting is not possible 
because blood cells are lysed directly after collection. Therefore, abundant transcripts in 
abundant cell types may conceal the more interesting less abundant transcripts from less 
abundant cell types. Particularly, the presence of  globin transcripts originating from re-
ticulocytes in whole blood samples may limit the sensitivity of  gene expression profiling 
experiments [14], since globin transcripts can constitute up to 70% of  the total whole 
blood mRNA population [17]. While in microarray experiments the presence of  globin 
transcripts may reduce the amount of  fluorescent label available for other transcripts but 
otherwise just results in a saturated spot on the microarray, the high abundance of  globin 
transcripts is more of  a concern in sequencing-based expression profiling studies. Since 
measuring absolute abundance, globin transcripts will be sequenced over and over again, 
while limiting the coverage of  other transcripts. 
To deal with the abundance of  globin transcripts in whole blood mRNA, several globin 
reduction protocols have been successfully used in gene expression studies [18-21]. The 
removal of  alpha and beta globin mRNA can be achieved by selective hybridization 
of  biotinylated globin sequence specific oligos with the globin transcripts and deplet-
ing them from the total mRNA population through magnetic beads [17]. Another ap-
proach developed by Affymetrix and PreAnalytiX utilizes 3’ specific peptide nucleid ac-
ids (PNAs) to inhibit reverse transcription during cDNA synthesis. Alternatively, a high 
abundance transcript depletion protocol adopts the properties of  the Kamtchaka crab 
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duplex specific nuclease to selectively reduce the most abundant RNA transcripts [22].
Our aim in the present study is to investigate the effect of  globin transcript reduction on 
the specificity and sensitivity of  digital gene expression profiling (deep SAGE).
Materials and Methods
Blood collection & RNA isolation 
Samples from six healthy individuals of  Caucasian decent (4 females, 2 males) aged 
from 39 to 70 years old were collected after informed consent and with ethical approval. 
Whole blood was drawn into PAX gene tubes (Qiagen, Venlo, The Netherlands) and 
inverted 10 times. Samples were allowed to equilibrate at room temperature for 2 hours, 
placed at -20oC overnight and stored at -80oC until further processing. Before total RNA 
extraction, samples were thawed overnight at 4oC and total RNA was isolated using 
the PAX RNA isolation kit following the manufacturer’s instructions, including DNAse 
treatment. RNA quality and the RIN values were determined using the RNA Nano Lab-
Chip assay (Agilent Technologies, Santa Clara, CA, USA). The concentration of  each 
sample was validated using the Nanodrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA).
Globin reduction
From each sample, 1.5 μg of  total RNA was treated using the GLOBINclear™ Human 
Kit (Ambion, Austin, TX, USA) according the manufacturer’s instructions. The kit con-
tains 10 globin sequence specific biotinylated oligonucleotides (http://www.freepatent-
sonline.com/y2006/0257902.html). Transcripts hybridized to the oligonucleotides are 
removed through streptavidin magnetic beads. Concentration and quality of  the samples 
were checked as described above.
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Quantitative real-time PCR
cDNA was synthesized from 1μg of  total RNA using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche, Mannheim, Germany) with Random Hexamer primers at 50°C 
for 1 hour. The primer sequences designed to target genes of  interest and the reference 
gene ACTB are described in Additional file 4. The qPCR was performed using 1μl of  
4x diluted cDNA, 2x FastStart Universal SYBR Green Master mix (Roche), 2.5 pmol 
forward primer,2.5 pmol reverse primer and PCR grade water to a total volume of  10μl. 
The reaction was performed using the LightCycler 480 (Roche) with initial denaturation 
10 min. at 95°C, followed by 45 cycles of  10 sec. denaturation at 95°C, 30 sec. annealing 
at 60°C and 20 sec. elongation at 72°C and  final elongation was performed 5 min. at 
72°C. This was followed by melting curve analysis from 60°C to 98°C with a ramp rate 
of  0.02°C per sec. The primer efficiencies and relative expression of  the transcript levels 
was determined using LinRegPCR_v11.3[29].
SAGE library production
SAGE libraries were produced according to the Illumina protocol [6]. In short, after 
hybridization of  1μg total RNA to polydT magnetic beads (Dynabeads, Invitrogen Life 
Technologies, Carlsbad, CA, USA), first and second strand synthesis was performed. 
The beads attached to the double stranded DNA were digested with NlaIII restriction 
endonuclease to produce short double stranded constructs starting at the most 3’ CATG 
of  the transcript. After ligation of  the GEX adapter 1, the construct was digested with 
MmeI to create a 21 base pair fragment downstream of  the GEX adapter 1. This frag-
ment was then ligated to GEX adapter 2 to complete the cassette. The adaptor ligated 
constructs were amplified by 15 cycles of  PCR and the products were loaded on 6% 
Novex TBE precast acrylamide gels (Invitrogen). The 96 base pair band corresponding 
to the NlaIII construct was excised and purified from the gel slice using the soak and 
crush method followed by ethanol precipitation. Sample quality was checked on a DNA 
1000 Lab-on-a-Chip (Agilent). Sequencing was performed at the Leiden Genome Tech-
nology Center on Illumina GA2 sequencer (Illumina, San Diego, CA, USA). Purified 
samples were diluted to 10nM and loaded on a single lane of  the flow cell where, after 
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cluster amplification, samples were put through an ultra short 18 cycle sequencing run.
Sequence processing
Illumina Pipeline Software version 1.5 was used for data sequence processing. The 
FASTQ files were analysed using the open source GAPSS_B(v2) pipeline (www.lgtc.nl/
GAPSS). All sequences were trimmed to 17 base pairs to remove the first lower quality 
base pair from the 3’ end of  the sequences. After trimming, the NlaIII recognition site 
(CATG) was added to the 5’ end of  the sequence to create the complete 21/22-mer nu-
cleotide sequences. Sequences were aligned using the Bowtie short read aligner (version 
0.12.7) against the UCSC hg19 reference genome, allowing for a maximum of  one mis-
match and a maximum of  two possible positions in the genome (options: -k 1 -m 2 -n 1 
--best --strata –solexa1.3-quals).
A custom Perl script was used to create reference region files from the SAGE region files 
that were composed of  the overlapping tags from all samples. A second Perl script was 
then used to link all individual region files to the reference region file, reporting the num-
ber of  tags in each individual region of  the reference region file. Finally, the reference 
region file was annotated with transcript information using BioMart (Ensembl build 60). 
For all reported downstream statistical and biological analysis only sequences aligned 
to known exons were used.  Analyses were performed at the gene level, and in case of  
multiple SAGE tags per gene, e.g. as a consequence of  alternative polyadenylation, tags 
were summed. The data discussed in this publication have been deposited in NCBI’s 
Gene Expression Omnibus and are accessible through GEO Series accession number 
GSE33701 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33701).
Statistical analysis
To identify genes detected at lower or higher levels, data files containing the count ex-
pression data were analyzed using the edgeR package (version 2.0.5) [30,31] in R (ver-
sion 2.12.0). Data was normalized creating libraries of  equal size (11 million tags). To 
determine differences in detection levels between the two groups an exact test for the 
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negative binomial distribution was used. The P values were adjusted for multiple testing 
using the Benjamini-Hochberg approach for controlling the false discovery rate (FDR) 
and genes were considered to be different between reduced and non-reduced samples 
when the P value was less than 0.01. For pathway enrichment analysis, the online tool 
DAVID was used. To identify gene biotypes, Ensembl genes IDs were uploaded to the 
BioMart site and supplied gene biotype attributes (Ensembl build 60, Homo sapiens 
genome reference GRCh37.p2). To examine if  transcripts are uniquely and consistently 
identified in the globin reduced or non-reduced samples only, we applied a tag count 
threshold of  5 tags or more and this threshold had to be met in 5 out of  the 6 samples in 
the respective group. 




Globin transcripts can successfully be reduced in whole blood 
samples
To investigate whether the RNA quality was affected by globin reduction, the RNA In-
tegrity Number (RIN) value was determined for each sample (summarized in Table 1) 
with a RIN value of  10 representing the highest RNA quality. On average, the RIN 
value was slightly lower in the globin-reduced samples compared to the non-reduced 
samples indicating a minor reduction in RNA quality. Additionally, we measured RNA 
concentrations before and after globin reduction and observed an RNA yield loss of  5-9 
%. General sequencing and alignment statistics are given in Table 1. To verify if  globin 
reduction was successful, the percentage of  globin transcripts was determined in the re-
duced and non-reduced samples. The most abundant transcripts in the non-reduced sam-
ples corresponded to globin alpha1 (HBA1), globin beta (HBB) and globin alpha2 (HBA2) 
(Figure 1). The percentage of  globin transcripts constituted on average 60% (52-76%) of  
total reported alignments and for the reduced samples this dropped to 0.1% - 0.4 % (Ta-
ble 1), demonstrating the efficiency of  the globin reduction protocol. The two transcripts 
Figure 1. Transcript abundance in the non-globin reduced samples. Pie chart showing the most 
abundant transcripts in whole blood (average of  6 samples). Hemoglobin alpha 1 (HBA1), hemo-
globin beta (HBB) and hemoglobin alpha 2 (HBA2) comprise the majority of  transcripts.
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that were most abundant after the globin transcripts, lysozyme (LYZ) and ribosomal 
protein (RPLP2) transcripts were detected at higher levels in the globin-reduced samples. 
In order to validate the next generation sequencing results we performed qPCR for HBA 
and HBB for 4 non reduced and reduced samples and the results confirmed the next 
generation sequencing results (see Additional file 1). To examine the reproducibility of  
globin reduction we performed a logarithmic transformation on the count data from the 
6 globin reduced samples and calculated the correlation. Correlation values ranged from 
0.88 to 0.94, showing good reproducibility after globin reduction (Additional file 2).
Figure 2. Differential expression of  non-globin reduced versus globin reduced whole blood samples
A. MA-plot (log concentration on x-axis, log fold-change on y-axis) showing that the majority of  
differentially expressed genes (P value < 0.01, indicated in red) are up-regulated while the 4 globin 
genes showed the strongest reduction. Genes with zero expression in one of  the groups are shown 
on the left end of  the plot. HBD: hemoglobin delta, HBB: hemoglobin beta, HBA1: hemoglobin 
alpha 1, HBA2: hemoglobin alpha 2. CXorf25 has a logConc of  -18.79 and a logFC of  -14.3 and 
is not shown on this graph. B. Heatmap of  normalised expression values of  21633 genes across 
the 6 non reduced and 6 reduced (R) samples where green depicts high expression and red low 
expression values.
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Differential gene expression differences between globin reduced 
and non-reduced samples 
To investigate if  more genes could be identified after globin reduction we used the edgeR 
Bioconductor statistical R package to examine differential gene expression between the 
6 globin reduced and 6 non-reduced samples. We identified 21,633 uniquely expressed 
genes in the 12 samples and 11,633 out of  these 21,633 genes were detected at significant-
ly higher levels (FDR 1%) in the globin reduced samples (Figure 2). There were 87 genes 
detected at significantly lower levels in the globin reduced samples. The transcripts that 
were the most significantly decreased (p-value) were the pseudogene CXorf25 and the 4 
globin transcripts globin delta (HBD), hemoglobin beta (HBB), hemoglobin alpha 1 
(HBA1), hemoglobin alpha 2 (HBA2) (see Table 2). Furthermore, 82 other non-globin tran-
scripts were significantly reduced by the globin reduction procedure (Additional File 3).
Gene Description Gene name logConc1 logFC2 P-Value FDR 
Pseudogene CXorf25 -18.79 -14.3 2.10e-54 3.68e-50 
Globin Alpha1 HBA1 -5.19 -7.59 7.48e-34 6.53e-30 
Globin Alpha2 HBA2 -6.43 -7.51 2.12e-33 1.23e-29 
Globin Beta HBB -5.99 -6.76 3.82e-29 1.66e-25 
Globin Delta HBD -12.87 -6.05 4.37e-25 1.52e-21 
APX/Shroom Family SHROOM4 -17.84 -5.37 6.66e-20 1.93e-16 
Ataxia/Rad3 ATR -15.71 4.57 6.80e-17 1.69e-13 
Pseudogene RP11-431J24.4 -21.08 6.1 9.66e-17 2.10e-13 
Trub sudouridine synthase TRUB1 -19.14 4.83 6.43e-16 1.24e-12 
Pseudogene CTD-2165H16.1 -18.82 4.71 1.48e-15 2.58e-12 
Table 2. Top ten most differentially expressed transcripts. The 4 most abundant globin transcripts 
are in the top five of  differentially down-regulated transcripts (¹ logConc - Overall concentration 
for a tag across the two groups compared, ² logFC - The log-fold change difference for the counts 
between the groups compared).
         Blood RNA Globin Depletion
91
2
To examine why 83 non-globin transcripts were reduced by the globin reduction proce-
dure, we examined possible non-target specific hybridization of  the globin oligos. Using 
the sequences of  the ten biotinylated oligonucleotides from the globin reduction kit we 
performed a blastn search against the human mRNA reference genome but only the 4 
globin transcripts that were found to be most significantly decreased in our globin-re-
duced samples showed significant hits in blastn. Moreover, oligonucleotide sequences 
were analyzed with RNAhybrid, an online tool for determining the minimum free hy-
bridization energy between a long and a short 
RNA [23] but no conclusive evidence was 
found for non-specific hybridization between 
oligonucleotides from the globin reduction kit 
and the 83 non-globin transcripts that were 
reduced in our globin-reduced samples. Final-
ly we wanted to investigate if  any of  the 83 
transcripts could have been co-captured with 
the globin transcripts. Hence we investigated 
whether there was sequence homology be-
tween the 83 top reduced transcripts and the 
globin transcripts but there was no indication 
of  co-capturing based on sequence homology. 
Furthermore, more than half  the transcripts 
reported as non-specifically detected at lower 
levels were derived from pseudogenes or ex-
pressed at very low levels.
Transcripts detected in globin reduced samples only
From the total number of  21,633 transcripts discovered in our SAGE experiments, 
10,368 were expressed above the threshold of  at least 5 tags in 5 out of  the 6 samples 
in both the globin-reduced and non-reduced group. We identified 2,112 transcripts in 
the globin-reduced samples that were not expressed above the threshold in the non-re-
Figure 3. Venn diagram displaying the num-
ber of  transcripts in at least 5 out of  6 sam-
ples at a level of  5 tags or more. Reducing 
the globin transcripts increases the number 
of  transcripts that can be reliably detected 
(2112 genes). 9121 genes were not consis-
tently expressed in either group.
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duced samples and 32 transcripts in the non-globin reduced samples that could not be 
detected in the globin-reduced samples (see Figure 3). Additionally, 9,121 transcripts 
were detected in globin-reduced samples only but did not reach the threshold (low abun-
dance transcripts).  Increasing the threshold tag number resulted in a higher number of  
genes detected by the globin reduced samples while the number of  genes only detected 
in non-reduced samples remained approximately the same. Furthermore increasing the 
threshold resulted in less genes identified by both groups. 
Functional enrichment and gene biotype analysis
For the 2,112 transcripts identified in the globin reduced samples only, we performed 
gene ontology (GO) term enrichment analysis using the online DAVID Bioinformatics 
Resources 6.7 [24] (see Table 3). The GO terms that were most significantly enriched 
were “metal and ion binding” and “DNA binding”, the latter including genes encod-
ing for proteins with roles in transcription and regulation of  transcription. We also per-
formed the same enrichment analysis for the 9,121 transcripts that did not reach the 
Table 3. GO term enrichment analysis using DAVID. Top 10 Gene Ontology terms found en-
riched by the DAVID online analysis tool in the 2,112 transcripts uniquely found in the globin 
reduced samples. P-value reflects the P-value from the hypergeometric test. CC-Cellular Compo-
nent, BP-Biological process, MF-Molecular function.
GO: Term Count Gene % P value 
MF Ion binding 383 23.7 7.90e-6 
MF Cation binding 380 23.6 4.30e-6 
MF Metal ion binding 379 16.4 2.20e-6 
MF Transition metal ion binding 272 16.9 9.80e-7 
MF Zinc ion binding 229 14.2 3.50e-6 
MF DNA binding 214 13.3 9.50e-4 
BP Regulation of  transcription 214 13.3 8.40e-2 
CC Intracellular non membrane bound organelle 210 13.0 1.30e-2 
BP Transcription 183 11.3 2.50e-2 
CC Plasma membrane part 176 10.9 3.70e-2 
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more stringent threshold. This group of  genes also showed significant enrichment for 
metal and ion binding proteins. Additionally, we observed enrichment in transcripts cod-
ing for cell surface receptors signal transduction proteins, G-protein coupled receptors 
and proteins involved in neurological processes. Since these transcripts are present in low 
copy numbers in our samples, these transcripts would benefit from globin reduction and 
even greater depth of  sequencing. 
There are around 20,000 protein-coding genes that together comprise only 2% of  the 
human genome [25]. However, a large fraction of  transcripts map outside known protein 
coding genes [26] and it is becoming clear that non-protein-coding RNAs play critical 
roles as transcriptional, post-transcriptional and chromatin-modifying regulators [27]. 
As such, we were interested in characterizing the gene biotype of  the 21,633 transcripts 
identified in our gene expression analysis (see Figure 4). We analyzed the transcripts 
Figure 4. Gene biotype distribution in transcripts with and without globin reduction. Percentage 
of  identified transcripts in the non-globin reduced and globin-reduced samples; low abundance 
transcripts consist of  transcripts detected at levels too low to be assigned to any of  the two pre-
vious groups. The 9121 low abundance transcripts contain relatively more processed transcripts, 
pseudogenes, large intergenic non coding RNAs (lincRNAs) and miscellaneous RNAs (mis-
cRNAs).We statistically compared the distribution of  the number of  transcripts over the different 
categories with a chi-square test and all pairwise comparisons were highly significant ( p<2.2e-16).
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according to the groups defined in Figure 3. The majority of  transcripts from all three 
groups were protein coding transcripts. However, there were subtle differences in the 
identified transcripts. The 2112 transcripts that were uniquely identified in the globin-re-
duced samples contained slightly elevated numbers of  pseudogenes, processed tran-
scripts and large intergenic non-coding RNAs (lincRNAs). The 9121 transcripts whose 
tag numbers were too low to be consistently ascribed to either of  the experimental groups 
contained relatively more pseudogenes.
Sequencing depth vs. globin reduction - Genes discovered
The previous results showed that by reducing the number of  globin transcripts before 
sequencing, the number of  different transcripts that can be identified increases. Next, 
we investigated how much additional sequencing is required to achieve this effect of  
globin reduction just by sequencing non-globin reduced samples at a greater depth. For 
this purpose we compared results from non-globin reduced RNA samples that were se-
quenced at high and low sequencing depth. At two times higher sequencing depth, the 
reported alignments as well as the number of  identified transcripts for each of  the sam-














7.8.106 11.6.106 29.2.106 32.0.106 16.5.106 15.9.106
Reported 
Alignments
4.7.106 5.5.106 23.6.106 25.6.106 9.8.106 9.4.106
Transcripts 
Detected
9,823 9,003 13,085 12,738 13,302 12,831
Table 4. Number of  transcripts identified across different sequencing depths. Two non-glo-
bin-reduced samples were sequenced twice, at low and high sequencing depths, and compared 
to the sequencing results from the same samples with reduction of  the globin transcripts.
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detected transcripts in globin-reduced samples is achieved at a sequencing depth of  ~15 
million reads while the same number of  transcripts is detected at a sequencing depth of  
~25 million reads in the non-globin reduced samples. In silico analysis was performed to 
determine at which sampling rate the threshold of  at least 5 tags in 5 out the 6 samples 
was reached. The difference in detected transcripts between the reduced and non-re-
duced samples at any given sequencing depth remained equal, indicating that even at a 
very large numbers of  reads (>60 million reads) whole blood samples are not sequenced 
to saturation (see Figure 5). 
 
Figure 5. Number of  transcripts detected at increased sampling rate. In silico analysis 
using the sum of  aligned reads (total number of  reads ~60 million) across each group 
(reduced, non-reduced). A random subset of  these aligned reads is then used to find the 
number of  detected transcripts across the two sample groups over the 5 tag, 5 out of  6 
samples threshold. The plot shows that at similar sequencing depths, there is a consis-
tently higher number of  transcripts detected in the globin reduced samples compared 
to the non-globin reduced samples.
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Discussion
We performed globin transcript reduction on RNA from human peripheral blood to 
investigate if  this improved the sensitivity of  SAGE digital gene expression profiling. In 
the non-reduced samples, globin percentages were highly variable between samples and 
ranged from 52% to 76%. These numbers match previous reports for globin transcript 
abundances in blood [17]. The globin reduction process with biotinylated oligonucle-
otides complementary to globin transcripts was successful since there was a >99.6% 
reduction in globin transcripts. This was consistent with previous studies [28]. We ob-
served that after globin reduction there was a slight decrease in total RNA quality as well 
as an RNA yield loss of  5-9%. The slight reduction in RNA quality and yield had no 
effect on the quality of  the data. From the 21,633 transcripts that were detected across all 
12 samples, 11,633 transcripts were detected at significantly higher levels in the 6 globin 
reduced samples, while only 87 transcripts were reported as detected at significantly low-
er levels. We can not explain why there were transcripts, other than the globin transcripts, 
found to be expressed at lower levels in the globin reduced samples. In silico analysis 
showed that this was not likely due to cross hybridization with the globin transcripts or 
with the globin oligonucleotides from the globin reduction kit.
 
We detected robust expression of  2112 transcripts in globin reduced samples that could 
not be detected in non-globin reduced samples. This is similar to what has been previ-
ously reported using classical microarray gene expression platforms [17]. The important 
advantage of  more detectable transcripts is that there will be increased statistical power 
to detect differences between samples. Furthermore, this increased number of  detected 
transcripts after globin reduction provides more information about low abundance tran-
scripts that could give new insights into the underlying disease mechanism. 
The reduction of  globin transcripts provides a practical and reproducible method for 
improving the number of  transcripts detected in human peripheral whole blood samples, 
and reduces required sequencing capacity by a factor two. DeepSAGE is a technique 
that detects short tags of  21-22 base pairs representing specific transcripts. For this rea-
son the data complexity is lower compared to other digital gene expression profiling 
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techniques such as whole transcriptome sequencing (RNA-seq). For RNA-seq, where 
the aim is to also identify all the transcript isoforms, saturation is definitely not reached 
at 25 million reads, which would make globin transcript reduction in blood even more 
advantageous for RNA-seq. 
 
Conclusions
The reduction of  globin transcripts together with whole blood collection methods, such 
as the PAX system, constitutes a reproducible and reliable method that increases the 
number of  transcripts detected in next generation sequencing-based gene expression 
profiling. This will increase the statistical power to detect disease relevant signatures in 
patient-control studies.
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Additional file 2. Correlation matrix for the globin reduced samples. Upper panels 
represent correlation values of  log transformed data with asterisks depicting signifi-
cance. Lower panels contain scatter plots of  log transformed globin reduced samples.
Additional file 4. qPCR primer Sequences. Primer sequences used for qPCR 
validation of  HBA, HBB transcript levels.
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Abstract
With several therapeutic approaches in development for Huntington’s disease, there is 
a need for easily accessible biomarkers to monitor disease progression and therapy re-
sponse. We performed next generation sequencing-based transcriptome analysis, of  total 
RNA from peripheral blood of  91 mutation carriers (27 presymptomatic and, 64 symp-
tomatic) and 33 controls. Transcriptome analysis by DeepSAGE identified 167 genes 
significantly associated with clinical total motor score in Huntington’s disease patients. 
Relative to previous studies this yielded both novel genes, and confirmed previously iden-
tified genes, such as H2AFY, an overlap in results which has proven difficult in the past. 
Pathway analysis showed enrichment of  genes of  the immune system and of  target genes 
of  miRNAs which are downregulated in Huntington’s disease models. Using a highly 
parallelized microfluidics array chip (Fluidigm) we validated 12 of  the top 20 significant 
genes in our discovery cohort and 7 in a second independent cohort. The five genes 
(PROK2, ZNF238, AQP9, CYSTM1, and ANXA3) which were validated independently in 
both cohorts present a candidate biomarker panel for stage determination and therapeu-
tic readout in Huntington’s disease. Finally, we suggest a first, empiric formula predicting 
total motor score from the expression levels of  our biomarker panel. Our data support 
the view that peripheral blood is a useful source to identify biomarkers for Huntington’s 
disease and monitor disease progression in future clinical trials.




Huntington’s disease (HD) is a heritable neurodegenerative disorder that manifests itself  
through cognitive, psychiatric and motor symptoms. The pathology is caused by an ex-
panded CAG repeat in the HTT gene, resulting in a mutant huntingtin protein. Patients 
also develop peripheral pathology [1] and increasing evidence indicate that peripheral in-
flammation has a role as a disease progression modulator [2]. HD brain tissue is charac-
terized by mutant protein aggregate formation and neuronal cell loss with transcriptional 
deregulation as a prominent feature [3,4]. Several mechanisms have been implicated in 
this deregulation such as: histone modifications, transcription factor impairment and 
aberrant miRNA expression [5]. For HD clinical trials it is important to identify disease 
progression biomarkers. Longitudinal studies have shown that imaging biomarkers and 
clinical measures provide valuable information [6]. However clinical measures can be 
subject to inter-rater variability and imaging is expensive. A biomarker should be able to 
identify changes before clinical symptoms, should be easily obtained and respond well 
to disease-modifying interventions. As it is impossible to measure molecular biomarkers 
in brain, the use of  more accessible tissues has been proposed, such as blood. Leuko-
cytes involved in immune system regulation, make blood an ideal source for identifying 
HD events such as peripheral inflammation. In addition, as huntingtin is ubiquitously 
expressed, mutant huntingtin-specific changes could also be reflected by gene expres-
sion changes in blood. Several studies have identified HD blood mRNA changes using 
microarray technology but it has proven difficult to validate these across studies [7-9]. 
Advances in next generation sequencing offer new inroads to study the transcriptome. 
The digital nature of  next-generation sequencing allows for accurate quantification of  
unknown transcripts, low- and high-abundance transcripts. Sequence-based methods 
allow the measurement of  known as well as unknown transcripts, thus obviating the 
past limitation to the microarray content. In addition, sequence-based methods are more 
precise than microarrays and more robust across experiments because of  much greater 
depth and the absence of  the background signal and cross hybridization issues that were 
associated with microarrays [10]. One such method, the 3’ digital expression profiling 
(DGE/DeepSAGE) creates 21 base pair sequences (tags) near the 3’ ends of  polyade-
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nylated mRNAs [11] and uniquely identifies transcripts using these tags. Thus by count-
ing the matching transcripts one can estimate differences in gene expression between 
samples across a large dynamic range. In comparison with full-length RNA sequencing, 
DeepSAGE has the advantage of  comprehensive coverage of  all (transcribed) genes at 
great depth, at the cost of  not detecting different splice variants. In this study we in-
vestigated the suitability of  blood to identify HD transcriptomic biomarkers, validated 
the outcome in an independent cohort and derived a first empiric panel of  biomarkers 
capable of  predicting HD motor scores. Finally, we examined whether patient gene ex-
pression profiles could provide information about HD affected biological pathways. 
Material and Methods
Cohort assessment and characteristics
Peripheral blood from 33 controls, 27 presymptomatic mutation carriers and 64 symp-
tomatic mutation carriers were collected for the discovery cohort and independent val-
idation cohort from 12 symptomatic mutation carriers and 11 controls. Collection was 
done with IRB approval and after informed consent. All subjects were examined by an 
experienced neurologist using the motor section of  the Unified Huntington’s Disease 
Rating Scale (UHDRS) as described previously [12]. All the controls were free of  known 
medical conditions. Age considered for the analysis was the age at the time of  blood col-
lection. For a detailed summary of  the study cohort’s average age, gender composition, 
UHDRS TMS and HD progression total functional capacity scores (TFC) see Supple-
mentary Table S3. 
RNA isolation and DeepSAGE library production
RNA isolation and cDNA library production was performed as described previously 
[13].  In short total RNA was extracted from PAXgene blood tubes (Qiagen, Venlo, The 
Netherlands) and 1 μg of  total RNA was used to synthesize double-stranded cDNA con-
structs for next-generation sequencing.




Illumina GA Pipeline (version 1.5.1) was used for data sequence processing. The 
FASTQ files were analyzed using the open source GAPSS_B pipeline (http://www.lgtc.
nl/GAPSS) as described previously[13]. In addition, a custom Perl script was used to 
obtain gene annotations from BioMart and a custom python script was used to count the 
tags in each Ensembl gene using the SAM output files from “bowtie”. To avoid batch 
effects, the samples were randomized during RNA isolation and DeepSAGE sample 
preparation. To identify potential sample swaps and contaminations all samples were 
checked for the correct expression of  XIST and RPS4Y1 gender specific genes. Batch 
effects were assessed using multidimensional scaling (MDS) plots for gender, sequencing 
flow cell and disease stage and by using the edgeR bioconductor package for RNA-Seq. 
The sequencing gene expression data used for this study have been deposited in the Gene 
Expression Omnibus (GEO) database under accession number GSE51799.
Fluidigm RT-qPCR
cDNA synthesis was performed using 1 μg of  total RNA from each blood sample and 
using random hexamer primers with the Transcriptor First Strand cDNA synthesis kit 
(Roche). cDNA was diluted 4 times and 1.25 μl of  each sample was preamplified using 
2.5μl of  2x Taqman pre-amplification master mix (Applied Biosystems) and 1.25 μl of  
the primer pool (0.2pmol each primer/μl). The preamplifications were performed using 
a 10 minute 95 °C denaturation step and 14 cycles of  15 seconds at 95° C and 4 minutes 
at 60° C. The preamplified reactions were diluted 5x times in H
2
0. Five microliters from 
a sample mix containing preamplified cDNA and amplification Master mix (20mM 
MgCl
2
, 10mM dNTPs, FastStart Taq polymerase, DNA binding Dye loading reagent, 
50x ROX, 20x Evagreen) was loaded into each sample inlet of  the 48.48 dynamic array 
chip (Fluidigm Corporation, San Francisco) and 5 μL from an assay mix containing  DA 
assay loading reagent as well as  forward and reverse primers (10pmol/μl) were loaded 
into each detector inlet. The chip was then placed on the NanoFlexTM 4-IFC Controller 
for loading and mixing. After loading the chip was placed on the BioMarkTM Real-Time 
PCR System using a cycling program of  10 min at 95°C followed by 40 cycles of  95°C 
for 15 sec and 60°C for 30 sec and 72 °C for 30 sec. Data were analyzed using the Bio-
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Mark Gene Expression Data Analysis software to obtain Ct values and/or ∆Ct values. 
Fluidigm data were corrected for differences in input RNA using the geometric mean of  
3 reference genes ACTB, HPRT and RPL22.The array accommodated reactions for all 48 
validation samples and 23 genes in duplicate (duplicate values were averaged).
Statistical analysis
All DeepSAGE downstream analyses were performed at the gene level, and in case of  
multiple SAGE tags per gene, for example, as a consequence of  alternative polyadenyla-
tion, tags were summarized. All the tag counts for a certain gene across all 124 samples 
were summarized. Low abundance genes with <124 tags were removed as were the top 
3 overabundant genes (HBA1, HBA2 and HBB). Gene expression analysis was performed 
using the “limma” package and the “voom” function for RNA-seq data and by applying 
linear modeling and empirical Bayes statistics [14]. The model tested gene expression 
as a function of  the subject’s total motor score (TMS), while accounting for gender, 
age and relative cell content (measured by the ratio of  hemoglobin tags versus total 
aligned tags per sample) as confounders. Fluidigm expression analysis was performed 
using the linear modeling function in R and by testing the individual ∆ct expression val-
ues against the subject’s TMS, while accounting for gender and age. Global test pathway 
analysis was performed using the same model as was used for the DeepSAGE analysis. 
For GO pathway analysis the top P value pathways that consisted of  a minimum of  10 
genes were reported. For IPA analysis the top 250 DeepSAGE genes were used (P value 
<0.001) For TMS prediction a linear regression model with a “lasso” penalty was fitted 
using the R package “penalized”, optimizing the lasso tuning parameter using leave-one-
out cross-validation [15].The effects of  age and gender were not penalized. 





Samples were sequenced at an average library size of  23.5 million tags. Alignment to 
the human genome resulted in an average library size of  20.4 million tags with at least 
one reported alignment (87.1%). A detailed description of  the sequenced samples RNA 
integrity numbers (RIN) and sequence alignment characteristics can be seen in Supple-
mentary Table S4. After removal of  very low abundance genes we could reliably detect 
a total of  16.657 genes. To find HD-specific stage or progression biomarkers the Deep-
SAGE gene expression data were modeled as a function of  the individual UHDRS total 
motor score (TMS); while accounting for gender, age and the percentage of  hemoglobin 
tags (a proxy for the reticulocyte content) as confounders. The TRACK HD study has 
shown that in presymptomatic HD gene carriers the motor score scale (0-124) is a strong 
predictor of  subsequent clinical conversion [6]. Our HD group consisted of  27 presymp-
tomatic (TMS=2.4±1.8) and 64 symptomatic (TMS=37.4±24.3).  After linear modeling, 
a total of  167 genes significantly associated with motor score at an adjusted P value of  
0.05 or less, suggesting that these constitute potential disease stage biomarkers. Of  these 
167 genes, 99 were positively associated with motor score and upregulated in HD sam-
Figure 1. Boxplots of  the DeepSAGE expression values for the top 3 upregulated genes dis-
covered from linear modeling with TMS and for all 124 samples. The plot confirmed our linear 
modelling analysis and demonstrated a gradual increase in gene expression across the different 
total motor score groups.
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ples compared with controls, while 68 were negatively associated and downregulated. 
The top 10 upregulated and top 10 downregulated genes are shown in Table 1. When 
we grouped the samples based on TMS we could confirm our linear modeling results. 
Boxplots for the top 3 upregulated genes showed a gradual increase in gene expression 
with increasing TMS (Figure 1). A full list of  all the genes significantly associated with 
TMS as well as with total functional capacity score (TFC) disease staging are provided 
in Supplementary Tables S5 and S6 respectively (available online). Reassuringly in the 
TFC based analysis, 60% of  the genes were the same as the TMS-based significant genes. 
Among the top TMS P value significant genes were genes involved in regulation of  cir-
cadian rhythm such as prokineticin 2 (PROK2), genes associated with motor learning 
such as protein tyrosine phosphatase non receptor 4 (PTPN4) and genes implicated in the 
development of  the brain cortex such as G protein coupled receptor 56 (GPR56) [16-18]. 
The genes with the biggest expression change but lacking statistical significance were 
the small nuclear RNA host gene 9 (SNGH9) and the major histocompatibility complex 
class II DQ alpha1 gene (HLA-DQA1). HLA-DQA1 has been previously reported as a 
candidate RNA biomarker in human lymphocyte microarray data from HD patients, 
ranking among the top most changed genes [9]. The highest expressed significant gene 
was S100 calcium binding protein A9 (S100A9) with a log2 expression value of  11.7 
while the lowest expressed significant gene was sperm acrosome associated 3 (SPACA3) 
with a value of  -2.8, indicative of  the high dynamic range of  the sequencing platform 
(211.7 - (-2.8) =23170 fold).
Using EBI Gene Expression Atlas (http://www.ebi.ac.uk/gxa/) and literature searches, 
we found that 40 of  the 167 genes had been previously reported as differentially ex-
pressed in at least one HD gene expression study with the same direction in expression 
change. These included mechanistic target of  rapamycin (MTOR), a potential target for 
therapy in HD, H2A histone family member Y (H2AFY), a gene whose transcript lev-
els have been recently reported to mark HD activity in human and mouse, CDC-like 
kinase 3 (CLK3) another gene from the top 99 genes from the previous study, and aqua-
porin 9 (AQP9), a gene that has been described as a potential biomarker in blood [8,9,19].
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Global test pathway analysis
To elucidate affected biological pathways in HD blood that were associated with TMS, 
we used the “Global test” bioconductor package [20]. We included KEGG pathways, 
GO terms and predicted / validated target genes of  miRNAs (Broad-GSEA). In the 
KEGG pathway analysis (see Supplementary Table S7) we found terms frequently re-
ported in HD and neurodegenerative disorder pathway analyses such as neuroactive 
ligand receptor interaction, amyotrophic lateral sclerosis and long term depression. We 
also found less common terms such as the pentose phosphate pathway (PPP), Jak-STAT 
signaling and type II diabetes mellitus. The genes that contributed most to PPP were 
glucose phosphate isomerase (GPI), aldolase A (ALDOA), phosphogluconolactonase 
(PGLS) and transketolase-like 1 (TKTL1) an enzyme linking PPP with the glycolytic 
pathway. Mitochondria-associated metabolic dysfunction and increased glycolytic rate 
have been previously associated with HD [21]. The Jak-STAT pathway, a common sig-
naling pathway used by many cytokines was characterized by the upregulation of  ser-
ine-threonine protein kinase (AKT1), suppressor of  cytokine signaling 3 (SOCS3), son of  
sevenless homolog 2 (SOS2) and interferon-alpha/beta receptor beta chain (IFNAR2). 
Finally, for diabetes for which an increased frequency in HD patients has been previous-
ly described, the most significant genes were MTOR and protein kinase C delta (PRKCD) 
[22]. In the GO analysis we identified terms such as NADP binding, positive regulation 
of  interleukin 6 production and response to cholesterol. The most significant genes for 
NADP binding were neuronal nitric oxide synthase 1 (NOS1), flavin containing mono-
oxygenase 4 (FMO4) and homocysteine methyltransferase reductase (MTRR). The de-
regulation of  genes linked to response to cholesterol could also be important since cho-
lesterol biosynthesis has been shown to be impaired in HD cells, while Leoni et al. have 
demonstrated that 24OHC, a brain cholesterol turnover marker, correlated with disease 
progression [23]. All the genes reported for response to cholesterol can be seen in a Glob-
al test covariate plot in Supplementary Figure S5A. This result was also in agreement 
with Chou et al. who showed that the mutant Htt protein suppresses the secretion of  
CCL5 [24]. The analysis for enrichment of  target genes of  miRNAs showed enrichment 
of  miR-138 and miR-218 targets. These miRNAs were found downregulated in YAC128 
and R6/2 HD mouse models [25]. For the miR-138 and miR-218 target genes, a separate 
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enrichment analysis, using DAVID (http://david.abcc.ncifcrf.gov), showed that terms 
enriched specifically for miR-138 target genes were histone modification and axon guid-
ance while terms enriched specifically for miR-218 target genes were ubiquitin like con-
jugation, proto-oncogene and mental retardation. Other potentially interesting miRNAs 
that were identified previously were miR-18a, miR-504, miR-337 and miR-492 [26],[27]. 
To further validate our “Global test” pathway analysis results and obtain a better visu-
al representation of  the interconnections of  the genes involved in the above biological 
processes we also analyzed our data through the use of  the Ingenuity Pathway Analysis 
(IPA) (Ingenuity® Systems, www.ingenuity.com). Top diseases and functions reported 
by IPA network analysis were nervous system development, skeletal and muscular disor-
ders but also immune cell trafficking and inflammatory response (Supplementary Table 
S8). The gene network plot for the genes and molecules involved in the IPA network 6 
and for skeletal and muscular disorders, connective tissue disorder and cancer are shown 
in Supplementary Figure S5B. Interestingly this gene plot interconnected terms such as 
histones, 26s proteasome, pro-inflammatory cytokines, Hsp70 and insulin; all of  which 
have previously been implicated in HD. Canonical pathway analysis using IPA further 
confirmed our initial “Global test” results since common pathways reported were those 
of  diabetes mellitus, Toll-like receptor and T cell receptor signaling. Finally, upstream 
regulators from our top genes were reported to be IL-2, IL-6 and IL-12 (complex) by IPA 
analysis, which was also in good correlation with the Global test analysis.
Validation
To validate the DeepSAGE gene expression results, we performed nanoliter RT-qPCR 
using the Fluidigm Biomark microfluidics chip [28], using 25 samples from the origi-
nal discovery cohort as technical validation, supplemented with 23 patient and control 
samples as a biological validation in an independent cohort. Twenty genes in total, all 
from our DeepSAGE list of  167 significantly differentially expressed genes, were exam-
ined; the top 12 based on P value, 6 further down the 167 gene list based on differen-
tial expression in previous HD studies (H2AFY, AQP9, ANXA3, RGS14, ZNF238, NOL3) 
and another 2 genes based on possible involvement in HD pathology (CEBPA, TAF15) 
[3,8,9,19,29-31]. Fluidigm data were analyzed using a linear model as a function of  
TMS, while accounting for gender and age. In the basic validation cohort, 12 out of  
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the 20 genes tested were significantly associated with TMS, while in the independent 
validation cohort, 7 out of  the 20 genes were significant (see Table 2). Most other genes, 
while not reaching significance, showed trends in the same direction as in the discovery 
cohort. Five of  the 20 genes (PROK2, ZNF238, AQP9, CYSTM1 and ANXA3) were the 
most robust and significantly associated with TMS in both the discovery and the inde-
pendent cohort. The intergroup relative expression levels of  these 5 genes across HD 
versus control samples, irrespective of  TMS, can also be seen in Figure 2. Finally, when 
the linear modeling analysis was performed on all Fluidigm samples (n=48), we were 
able to validate 12 of  the 20 genes tested (see rightmost column of  Table 2).
Biomarker motor score prediction
To evaluate which panel of  genes would optimally predict TMS, we fitted a linear re-
gression model with a “lasso” penalty using the Fluidigm expression data, age and gen-
der as predictors and TMS as the response. The gene expression values of  three genes 
Figure 2. Relative expression of  the most significant Fluidigm RT-qPCR genes across the two 
independent cohorts for controls and HD patients. Asterisks represent statistical significance 
from a student’s t-test (* P<0.05, ** P<0.01). Error bars represent SEM values.
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(AQP9, ANXA3 and ARL4C), together with age and gender, were the best predictors of  
TMS. The last gene (ARL4C) was non-significantly downregulated in HD blood and 
specifically served the purpose of  enlarging the “biomarker chip” set towards tolerance 
for smaller individual gene changes, providing additional informativeness. The results 
of  the cross-validated prediction analysis can be seen in Figure 3. The prediction model 
performed better for earlier disease stages (Stage I, II), while it was less accurate for later 
stages (Stage III-V) and especially for patients with a motor score of  50 points and over. 
Only one patient was assigned a predicted TMS greater than 50 points (patient no.29). 
This patient was the oldest HD carrier (>70 years).  We also observed that for one patient 
the blood-based signature indicated a higher predicted motor score compared to the clin-
ical motor score. This could be explained by the fact that this patient had a much lower 
TFC score (TFC=4) compared to other patients with similar motor score, indicative 
of  a more advanced disease stage. Finally, the control sample with the highest clinical 
motor score (control no.4) was our oldest control sample (69 years) and also received a 
higher predicted score. When we plotted the DeepSAGE gene expression levels of  these 
3 genes across the controls, the presymptomatic carriers and the different HD TFC-based 
disease stages we could confirm that for ANXA3 and AQP9 there was an increase in gene 
expression even in the presymptomatic stage. For ARL4C, contrary to ANXA3 and AQP9 
there was a decrease in gene expression, the expression changes were more prominent 
in the more advanced disease stages and hence provided complementary information 
to the other two genes (Figure 4). On the basis of  this analysis, we formulated a TMS 
predictive equation to measure the disease stage based on gene expression of  the 3 genes 
(see below Figure 4).
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Figure 3. Plot of  clinical TMS against cross-validated predicted TMS based on Fluidigm 
RT-qPCR gene expression data. The cross-validated motor score is predicted for each sub-
ject by a model trained on a data set in which the subject itself  was left out. Stage classifi-
cation was based on total functional capacity (TFC) scores (Stage I, II = TFC score 7-13/
Stage III-V=TFC score 0-7).
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To date, thousands of  disease biomarkers have been published while <100 have been 
validated in independent cohorts [32]. This inability to validate disease biomarkers has 
been attributed to the lack of  large enough study cohorts as well as standardization in 
sample collection and storage [33]. For HD, validation has been even more challeng-
ing as the disease presents itself  through a variety of  symptoms and progression rates. 
For these reasons we performed gene expression profiling, taking advantage of  the sen-
sitivity of  next-generation sequencing and Fluidigm technologies, and our experience 
in standardized blood collection and sample analysis[34,35]. Using the UHDRS TMS 
as a clinical parameter we identified a set of  167 genes differentially expressed in HD 
blood. Furthermore, we validated our findings by a targeted approach, using an entirely 
different technology. Technical validation (in the same cohort) confirmed 12/20 of  the 
discovered genes and biological validation (in a different cohort) confirmed 7/20 of  the 
discovered genes in a different cohort. Our discovery and validation cohorts (n=124 and 
n=48) are to our knowledge among the largest to have been used in HD gene expression 
studies. In contrast to previous studies, we have selected a sizable group of  20 genes for 
validation in duplicate (~2300 reactions). Indeed, the very fact that so many of  the top 
20 discovered genes can be validated argues in favor of  the robustness of  the discovery 
approach. Genes with more variation or smaller changes in principle are more difficult 
to validate in a small cohort. Yet, we should stress that these biomarkers presently con-
stitute a candidate biomarker set that requires further validation in other HD cohorts 
before further used in a clinical setting.
The Fluidigm qPCR analysis yielded a panel of  5 genes (PROK2, ZNF238, AQP9, 
CYSTM1 and ANXA3) as a potential HD biomarker set and this was validated in both 
the original cohort and an independent validation cohort. PROK2 is expressed in the 
suprachiasmatic nucleus (SCN) and has been proposed to have a role in the regulation 
of  circadian rhythms [17]. Circadian rhythm alterations have been shown to correlate 
with cognitive impairment in HD [36] and in HD models pharmacological imposition 
of  sleep slows cognitive decline and reverses deregulation of  PROK2 [37]. As a blood 
marker of  HD progression PROK2 is very promising, since this could also be reflecting 
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brain changes. ZNF238 is a transcriptional repressor involved in brain development and 
myogenesis [38] and increasing evidence suggests that gene repression mechanisms are 
associated with HD [39,40]. This is in agreement with the reported involvement in HD 
of  H2AFY, which is also involved in transcriptional repression and further studies link 
HD with SP1, another zinc finger protein [41]. Aquaporins are water selective channels 
with possible roles in the nervous system and expression levels were upregulated after 
brain injury [42]. The presence of  AQP9 in blood could represent peripheral or central 
inflammatory events since a recent gene expression study showed that the mRNA levels 
of  AQP9 and four other genes can discriminate patients with chronic inflammation from 
controls [43]. CYSTM1 is a relatively unknown gene and bioinformatics analysis has 
demonstrated a  role in stress response and confer tolerance to heavy metals such as cad-
mium and copper [44]. Finally ANXA3 was upregulated in two neuronal injury models 
[45],[46]. It is important to note that the levels of  annexin ANXA1 have also been found 
upregulated in a previous gene expression study in HD blood [8].
Our pathway analysis showed a wide range of  processes changed in HD. The most 
prominent terms pointed towards the involvement of  the immune system. It has been 
suggested by previous studies that pro-inflammatory cytokines such as IL-6, IL-8, and 
TNF-α can be used as peripheral HD biomarkers [47,48]. Other terms such as diabe-
tes mellitus could also be interesting since mouse models of  HD can develop diabetes 
mellitus [49], and it was shown that type II diabetes exhibits common features with oth-
er neurodegenerative disorders [50]. Finally, we discovered enrichment of  target genes 
of  miRNAS (miR-138/218) previously reported to be downregulated in HD models. 
This warrants further investigation as miR-9 was found to be downregulated in human 
HD brain samples and target complexes, such as REST, that regulates neuronal gene 
expression in non-neuronal tissues [51]. A disadvantage of  whole blood may be con-
sidered its cellular heterogeneity. The more informative white blood cells comprise a 
small percentage of  the total cell population, while 95% of  blood consists of  red blood 
cells, with hemoglobin transcript percentages, ranging from 30-90%. This could well 
account for the fact that until now less sensitive techniques failed to replicate results 
between different HD blood microarray studies [52]. For the same reason, in the past, 
most expression studies used isolated peripheral blood mononuclear cells. However, it 
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is not always possible to process samples directly after collection and preparation delays 
have been shown to induce biases [53]. In the present study, taking advantage of  the 
digital nature of  sequencing, we identified differentially expressed genes across a wide 
dynamic range, with high sensitivity, directly from whole blood. This provides a clearer 
image of  the transcriptional alterations in HD; although biomarkers with higher expres-
sion will be more useful and easier to detect with less sensitive routine techniques. Our 
motor score prediction analysis showed that the gene expression predictive power was 
stronger for early-stage and weaker for later-stage patients. While this could be explained 
by the increasing impact of  generalized tissue degeneration in late disease stages, the 
increased reliability in earlier stages is in fact of  major benefit as, notably in this early 
phase, robust therapeutic readouts are challenging. Furthermore, previous gene expres-
sion studies have found small individual gene expression changes in HD blood. In the 
future and for a potential “biomarker chip” to survive further validation, a larger group 
of  genes may be required that will better allow for variation in individual gene expression 
changes. For this reason, we used the predictive capabilities of  the LASSO algorithm to 
see which genes would jointly perform most optimally in UHDRS TMS prediction. The 
formula we have derived links a small set of  easily definable gene expression levels to the 
UHRDS Total Motor Score, and is thus a promising candidate biomarker set to monitor 
disease state, progression and putative therapeutic effect of  interventions. Taking into ac-
count the great symptomatic variability in HD patients, different sets of  biomarkers can 
be further trained and optimized, depending on the disease stage that is most prominent 
in the group of  patients included in each study.
Considering the complexity of  HD most likely a collection of  biomarkers will best define 
disease progression and response to therapy. The biomarker changes found in this study 
monitor disease progression in blood and may be relatively independent of  the changes 
taking place in brain. Such biomarkers, if  validated clinically, may be useful  as surrogate 
markers to test the effectiveness of  therapeutic strategies even when they may not have a 
robust relationship with actual clinical endpoints [54].
Owing to the design of  our study, comparing various HD stages with unaffected con-
trols, we cannot exclude that the detected changes might also (partly) track progression 
of  other neurodegenerative diseases. Thus, prior to putative diagnostic application, this 
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needs to be further assessed. However, this does not reduce the potential differentiating 
significance of  this biomarker panel for prognostic application in a known (pre)symp-
tomatic HD carrier setting. 
In conclusion, we describe the development of  a panel of  candidate HD biomarkers 
which can be easily measured by transcript analysis of  whole blood and which may have 
application in disease staging and the monitoring of  therapeutic effectiveness.  Longitu-
dinal and cross sectional studies in additional cohorts will be needed to further validate 
this panel before its application in the clinic. Finally, the assessment of  the disease rele-
vance of  the  genes involved may well contribute  to finding new HD therapeutic targets. 
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Supplementary Table S4. Sample RNA and sequencing quality characteristics for all 









Average Percentage of Total 
Reads Aligned a
87.1% (20.4 M)
(73 – 97 %)
Average Percentage of Total 
Reads Supressed b
9.37 % (2.2 M)
(2 – 17 %)
Average Percentage of Total 
Reads Failed To Align
3.54 % (0.8 M)
(0.6 - 15 %)
a At least one reported alignment.
b Bowtie –m option - suppress all alignments for a particular read or pair if  more than 2 
reportable alignments exist for it.
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Metabolic changes have been frequently associated with Huntington’s disease (HD). At 
the same time peripheral blood represents a minimally invasive sampling avenue with 
little distress to Huntington’s disease patients especially when brain or other tissue sam-
ples are difficult to collect.
Objectives
We investigated the levels of  163 metabolites in HD patient and control serum samples 
in order to identify disease related changes. Additionally, we integrated the metabolom-
ics data with our previously published next generation sequencing-based gene expression 
data from the same patients in order to interconnect the metabolomics changes with 
transcriptional alterations.
Methods
This analysis was performed using targeted metabolomics and flow injection electro-
spray ionization tandem mass spectrometry in 133 serum samples from 97 Huntington’s 
disease patients (29 pre-symptomatic and 68 symptomatic) and 36 controls.
Results
By comparing HD mutation carriers with controls we identified 3 metabolites signifi-
cantly decreased in HD (serine and threonine and one phosphatidylcholine - PC ae 
C36:0) and an additional 8 phosphatidylcholines (PC aa C38:6, PC aa C36:0, PC ae 
C38:0, PC aa C38:0, PC ae C38:6, PC ae C42:0, PC aa C36:5 and PC ae C36:0) that ex-
hibited a significant association with disease severity. Using workflow based exploitation 
of  pathway databases and by integrating our
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metabolomics data with our gene expression data from the same patients we identified 
4 deregulated, phosphatidylcholine metabolism related, genes (ALDH1B1, MBOAT1, 
MTRR and PLB1) that showed significant association with the changes in metabolite 
concentrations.
Conclusion
Our results support the notion that phosphatidylcholine metabolism is deregulated in 





Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder that 
presents itself  through motor dysfunction, psychiatric disturbances and cognitive de-
cline. The pathology is caused by an expanded CAG repeat in the HTT gene, resulting 
in a mutant huntingtin protein [1]. A characteristic of  HD is mutant protein aggregate 
formation and neuronal cell loss in the brain but it is also known that HD patients de-
velop peripheral tissue symptoms such as muscle atrophy, impaired glucose tolerance 
and weight loss [2,3]. The mutation for HD was discovered more than 20 years ago and 
much is known about the underlying disease mechanisms [4]. Moreover, recent studies 
show that lowering mutant huntingtin protein levels using RNAi is a promising thera-
peutic approach that is close to clinical trials [5,6]. This highlights/prompts the need for 
biomarkers that track disease progression and measure clinical trial therapeutic effec-
tiveness. 
Deregulation of  energy and metabolic pathways have been repeatedly implicated in HD 
[7-10]. Specifically, defects in lipid homeostasis have been proposed as contributors to 
disease onset [11-13]. Additionally, total cholesterol was found to be significantly re-
duced even outside the brain when human fibroblasts where cultured in lipoprotein-de-
prived serum [14]. Previous studies using HD transgenic models and human caudate 
samples have shown a deregulation of  genes involved in glycosphingolipid metabolism, 
selected brain gangliosides as well as neutral and acidic lipids. Additionally, Wang and 
colleagues were able to discover metabolic hormonal plasma signatures in presymp-
tomatic and symptomatic HD patients suggesting that in HD metabolic hormone se-
cretion and energy regulation is affected [15]. Previous mass spectrometry studies have 
shown differences in the serum metabolome of  transgenic HD mice and wild type con-
trols with a similar trend in human samples implicating changes in fatty acid break-
down and certain aliphatic amino acids [16]. Consequently such approaches that use 
mass spectrometry metabolomics on brain as well as non-nervous system tissue con-
stitute a promising approach for discovering novel HD metabolomics biomarkers [17].
Longitudinal studies have shown promising results in clinical and imaging HD biomark-
er discovery, but many of  these biomarkers are either expensive or subject to inter-rater 
variability [18]. A good biomarker should identify changes before clinical manifestation, 
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should be easily obtained and should respond robustly to disease-modifying interven-
tions. Increasingly, metabolomics technology is used in biomarker studies because it 
can identify intermediate biomarkers of  deregulated genomic pathways [19,20]. Further-
more, metabolomics identifies changes that occur downstream of  the gene expression 
level. This applies particularly well in HD since it is recognized that the mutant protein 
causes genome wide transcriptional deregulation [21,22]. The mutant huntingtin protein 
is ubiquitously expressed, and gene expression deregulations can be found in various HD 
tissues and organs. Furthermore, metabolite changes in blood may reflect changes in tis-
sues that have been in contact with blood [23] and as it is impossible to measure molec-
ular biomarkers in the brain, peripheral blood has been proposed as a viable alternative 
[24]. Nonetheless, the cellular heterogeneity of  blood together with the data complexity 
produced by non-targeted mass-spectrometric protocols, make it difficult to quantify the 
levels of  all metabolites simultaneously. Therefore, we have used a targeted metabolo-
mics approach that measures the concentration of  a selected group of  HD relevant, key 
biological compounds (such as amino acids, acyl carnitines, hexoses and glycerophos-
pholipids) in a semi-high throughput manner to identify such metabolomics markers. 
The aim of  this study was to detect metabolic markers of  HD status and progression as 
well as disease deregulated metabolic pathways. Our approach was based on targeted 
mass-spectrometry using the Biocrates AbsoluteIDQTM p150 [25] kit  to measure me-
tabolite levels in serum from HD carriers and controls. We then tested for the association 
of  the metabolite levels with HD mutation status, and well accepted clinical progression 
scores and stages such as the Unified Huntington’s Disease Rating Scale (UHDRS) total 
motor score (TMS) and total functional capacity (TFC) score based stages. Since the 
integration of  disparate biological data types like metabolomics and transcriptomics can 
provide a more complete picture of  diseases we correlated our metabolomics data with 
our publicly available whole genome expression profiling data from the same patient 
cohort and investigated functional relationships between the metabolite changes and the 





Metabolite concentrations were determined using the targeted metabolomics kit Abso-
luteIDQ™ p150 (Biocrates Life Sciences AG, Innsbruck, Austria) and flow injection 
electrospray ionization tandem mass spectrometry (FIA-ESI-MS/MS). A total of  163 
different metabolites were quantified simultaneously by the platform in 10 μL of  serum. 
The metabolite panel consists of  14 amino acids, Hexose (H1), free carnitine (C0), 40 
acylcarnitines (Cx:y), hydroxylacylcarnitines (C(OH)x:y), and dicarboxylacylcarnitines, 
15 sphingomyelins (SMx:y) and N-hydroxyacyloylsphingosyl-phosphocoline (SM(OH)
x:y), 77 phosphatidylcholines (PC, aa=diacyl, ae=acyl-alkyl) and 15 lyso-phosphatidyl-
cholines. Lipid side chains are denoted as Cx:y , where x represents the number of  car-
bons in the side chain and y the number of  double bonds. The assay procedures of  the 
p150 kit as well as the metabolite nomenclature have been described in detail previously 
[25]. Sample handling was performed by a Hamilton Microlab STARTM robot (Hamil-
ton Bonaduz AG, Bonaduz, Switzerland) and an Ultravap nitrogen evaporator (Porvair 
Sciences, Leatherhead, U.K.), beside standard laboratory equipment. Mass spectromet-
ric (MS) analyses were done on an API 4000 LC-MS/MS System (Sciex Deutschland 
GmbH, Darmstadt, Germany) equipped with a 1200 Series HPLC (Agilent Technolo-
gies Deutschland GmbH, Böblingen, Germany) and a HTC PAL auto sampler (CTC 
Analytics, Zwingen, Switzerland) controlled by the software Analyst 1.5. Data evalu-
ation for quantification of  metabolite concentrations and quality assessment was per-
formed at the Genome Analysis Center of  the Helmholtz Zentrum München using the 
MetIDQ™ software package, which is an integral part of  the AbsoluteIDQ™ kit. Inter-
nal standards served as reference for the calculation of  metabolite concentrations in μM.
Serum collection
Peripheral blood was collected from 29 presymptomatic, 68 symptomatic and 36 con-
trol, non-fasting individuals with institutional review board approval and after informed 
consent. For serum sample isolation, blood was collected in BD vacutainer Z tubes (no 
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additives) and was allowed to clot for 1 hour at room temperature. Tubes were spun at 
1300 g for 10 minutes at room temperature, were aliquoted and stored at -80 °C. Detailed 
information about the UHDRS clinical scores and CAG repeat lengths of  all the patients 
and controls as well as gender, age and BMI information can be found in Supplementary 
File 1.
Quality controls
To ensure the robustness of  downstream statistical analyses, all data provided from 
the MetIQ software package were subjected to three quality control steps. For the first 
step the coefficient of  variance was calculated for each experimental plate.  To achieve 
this five aliquots of  a reference plasma pool were measured on each plate together with 
the cohort samples. The coefficient of  variance was calculated as the standard devi-
ation to mean ratio for all five reference samples per metabolite and per experimen-
tal plate. All metabolites with a mean coefficient of  variance of  all plates, higher than 
25 % were excluded from further analysis. All metabolites with a missing value rate 
larger than 5% were also excluded. In the second step any outlying data points with 
a value greater than mean +/- 5 SD of  all measurements for this metabolite were ex-
cluded. Additionally, two Huntington disease samples were excluded due to high 
BMI values (outliers). For samples with less than, or equal to, three independent out-
lying points only the independent data points themselves were excluded. After these 
quality control steps 114 out of  163 metabolites and 133/138 samples remained. Af-
ter the above steps, when missing values were detected these were imputed using the 
R package “mice”. Finally, all metabolite concentrations were transformed using 
natural logarithm and before applying the experimental linear modeling analysis. 
Statistical analysis
To identify significant differences between the HD and control samples, the statistical 
analysis software R (Version 3.1.2, http://www.r-project.org/) was used. After the me-
tabolite concentrations were log-transformed, linear modelling statistical tests were ap-
plied. In specific, in the first model (disease status) the HD mutation carriers’ and control 
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individuals’ groups were coded as the main covariate and tested in a linear model using 
gender (categorical), age and BMI as additional (continuous) covariates. In the second 
model (disease severity) a four group categorical variable vector was used as the main co-
variate. The following groups were defined: Group 1 (n=36) – control, Group 2 (n=29) –
pre-symptomatic (TMS score <=5), Group 3 (n=31) – symptomatic (TMS>5, TFC score 
13-7) and Group 4 (n=37) – advanced symptomatic individuals (TMS score>5, TFC 
score of  0-6). For both models the final P value that was used to judge the validity of  our 
findings was extracted using the ANOVA function on the two nested linear models; the 
reduced linear model containing only the covariates of  gender, age and BMI and the full 
model additionally containing the main disease group categorical covariate. Since many 
identified metabolites showed a high degree of  correlation (see Supplementary File 2), 
the Bonferroni method was judged too strict for multiple testing correction. Therefore, 
the experiment-wide significance threshold that was used was 1.34E-03. This value 
was calculated using the matrix spectral decomposition method and the eigenvalues of  
the metabolites correlation matrix (matSpDlite) [26-28]. Bar plots for all metabolites 
that passed quality control were created using the Platform for RIKEN Metabolomics 
(PRIMe) tool for Microsoft excel [29]. The PLS-DA analysis across controls, presymp-
tomatic and symptomatic HD carriers was performed using the corresponding function 
of  the MetaboAnalyst v.3.0 online tool for metabolomics data [30].The top, pair ratio 
associations for all possible metabolite pair ratios were calculated through log transfor-
mation of  the ratios and the p-gain value was calculated from the individual P values of  
the ratio metabolites. In specific, p-gain is defined as the fold decrease in the P value of  
association for the pair of  metabolites compared to the lower of  the two P values for the 
single metabolites [31].
Integration of  metabolomics with transcriptomics analysis
Gene expression data from a previously published dataset [32] were extracted using the 
scaled data object from the “voom” function of  the “limma” package designed for RNA-
seq data analysis [33]. The data for both the genes and the metabolites were regressed for 
the effect of  age, gender and BMI. The gene expression data were regressed for cellular 
hemoglobin percentage (hemoglobin alpha and beta sequencing count tags) as a proxy 
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of  the cell reticulocyte count [34]. For the extraction of  the genes that were related to the 
metabolites the metabolic pathway databases from the Kyoto Encyclopedia of  Genes 
and Genomes KEGG [35] (release 63) and BioCyc (version 16) were accessed for re-
trieving background knowledge for each metabolite [36]. Two interrogation schemes 
were employed: pathway scheme and reaction scheme. In a pathway scheme, for a given 
metabolite, all the pathways that it participated in were determined followed by the re-
trieval of  all the genes that participated in these pathways. In a reaction scheme, given a 
metabolite, all the reactions that it was part of  and the compounds that participated in 
these reactions were determined [36].
For the integrated metabolomics and transcriptomic pathway analysis, the community 
driven resource of  curated pathways WikiPathways [37] was used to identify common 
pathways. The WikiPathways human pathway collection is the largest and most active 
collection per species. In terms of  coverage of  unique human genes, WikiPathways is 
comparable to KEGG. To investigate which metabolite-gene pathways overlapped we 
used all 10 significant metabolites (8 phosphatidylcholines and 2 amino acids) and the 
top 200 genes from our above linear modeling, as the input to the WikiPathways Web 
Service. Since pathway information for individual phosphatidylcholines is lacking, we 
also included the compounds at the phosphatidylcholine compound class level and their 
isomers (1,2-diacyl-sn-glycero-3-phosphocholine, alkyl,acyl-sn-glycero-3-phosphocho-
line and 1,2-diacyl-sn-glycero-3-phosphocholine(1+)) according to the Chemical Entities 





Using the Biocrates p150 kit we quantified serum concentrations of  163 metabolites 
in 133 serum samples from 97 HD mutation carriers and 36 controls. After quality 
control, 114 of  the initial 163 metabolites could be reliably detected and these were 
used for further analysis. These 114 metabolites consisted of  14 amino acids, 7 carni-
tines, 10 lyso-phosphatidylcholines, 69 phospatidylcholines, 5 hydroxysphingomyelins, 
8 sphingomyelins and 1 hexose. Supplementary File 3 (available online) contains data 
distributions of  all 163 metabolites, the metabolites that were excluded and their con-
centrations relative to the platform limit of  detection (LOD) and lower limit of  quan-
tification (LLOQ). In order to analyze the group structure of  the metabolomic dataset 
across controls, presymptomatic and symptomatic HD patients, we performed a partial 
least square discriminant analysis (PLS-DA). The symptomatics group (group 3 and 4 
combined, TMS >5) exhibited a clear shift from the control (group 1) and the pre-symp-
tomatic (group 2) samples. The scores plot for the symptomatics, pre-symptomatics and 
control groups and for the first two principal components can be seen in Figure 1A while 
the relative contributions and the relationships between the metabolites can be seen in 
the loadings plot of  Figure 1B. The observed concentration levels for all 114 metabolites 
across all four groups can be seen in Supplementary File 4 (available online). To identify 
which metabolites were significantly different in HD, the concentration changes of  the 
detected metabolites were tested using a linear regression model between HD mutation 
carriers versus control individuals and a linear regression model using four disease se-
verity stage groups as described in the Material and Methods section. We identified 3 
metabolites significantly changed in the HD mutation carriers vs controls analysis and 
8 metabolites significantly changed in the 4 disease stage group analysis that associated 
with disease progression (adj.P.val < 1.34E-03) (see Table 1). In the two group analysis 
the amino acids serine and threonine were higher in HD mutation carriers while the 
phosphatidylcholine acyl-alkyl C 36:0 average level was lower (see Figure 2). In the 4 
group analysis, 8 metabolites in total passed the significance threshold. 
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Table 1. Table of  the top 10 metabolites resulting from linear modeling analysis of  me-
tabolite concentrations between HD mutation carriers and controls and accounting for 
disease status (top) or disease progression group (bottom) and gender, age and BMI. P 
values represent significance probability values (Pr(>F)) from the two-way ANOVA cal-
culation on two (nested) linear models accounting for disease status or disease stage re-
spectively (measurement variables) and gender, age and BMI (nominal variables). Me-
tabolites that pass the adjusted p value threshold are highlighted in bold. Concentration 
changes were obtained from the fitted data of  the metabolites using the full linear statis-
tical model (see above) and disease state and stage respectively as the main covariate.
Figure 2. Boxplots of  concentration levels of  metabolites that were significantly different 
between control individuals and HD mutations carriers. Numbers represent the group sizes 
and asterisks represent significance values from linear modelling analysis. Colored dots rep-
resent individual sample concentrations. Asterisks represent significance probability values 
(Pr(>F)) from the ANOVA calculation of  the single (full – see methods) linear model account-
ing for disease status, gender, age and BMI.   * = P-value < 0.05, *** = P-value < 0.001
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These 8 metabolites were exclusively acyl alkyl and di-acyl phosphatidylcholines and 
were lower in HD versus controls and associated with increasing disease progression (for 
the top 5 metabolites see Figure 3). In the 4 group analysis serine was also in the top 10 
metabolites but failed to pass the adjusted P value significance level.
Association of  metabolite pair ratios with disease status and 
severity
Previous studies have shown that calculating the ratios of  individual metabolite con-
centrations can reduce dataset variation. Furthermore, such metabolite ratio changes 
have been connected to altered enzymatic reactions and pathways, can be used as an 
approximation of  the associated enzymatic activity [39,40] and ratios of  specific pairs 
of  metabolites have been suggested as biomarkers [41,42]. For this reason, we calculat-
ed all the pairwise ratios of  the detected metabolites and tested for the association of  
their ratios using the same two linear models. The resulting associations were ranked 
according to their p-gain values. The results for the two group (HD vs controls) analysis 
and the four group analysis can be seen in Supplementary File 5. We observed that in 
the two group analysis the results were dominated by inter- phosphatidylcholine ratios, 
as well as ratios of  phosphatidylcholines to serine and threonine. Additionally, one of  
the top p-gain values was that of  the arginine to carnitine ratio. Most of  the ratios of  
the sphingolipids and sphingolipids to amino acids were lower in HD carrier samples. 
The metabolite pair associations with controls, pre-symptomatic and the 2 symptomatic 
groups revealed similar results. The highest p-gain values were exhibited by inter-phos-
phatidylcholine ratios but also phosphatidylcholines and the hydroxy-sphingomyelin 
C16:1 (SM.OH.C16:1). The 4 group disease progression analysis was also characterized 
by the absence of  any amino acids in the top p-gain analysis similar to the individual 
metabolite analysis. These results confirm the changes in phosphatidylcholines levels in 
the disease and strengthen the potential of  the use of  (pairs of) phosphatidylcholines as 
markers of  disease progression since variation is reduced.
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Figure 3. Boxplots of  concentration levels 
of  significant metabolites between 4 groups: 
controls, presymptomatic, symptomatic and 
advanced symptomatic HD mutation carri-
ers. Numbers represent the group sizes and 
asterisks represent significance values from 
linear modelling analysis. Colored dots rep-
resent individual sample concentrations. 
Black dots represent outliers. Asterisks repre-
sent significance probability values (Pr(>F)) 
from the ANOVA calculation of  the single 
(fullsee methods) linear model accounting 
for disease stage group, gender, age and BMI. 
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Integration of  metabolomics with transcriptomics
To further explore potential molecular connections of  the identified metabolites with 
HD relevant or novel disease state/progression mechanisms we combined our targeted 
metabolomics dataset with our previously published next-generation sequencing gene 
expression data from the same patient and control cohort [32]. For our initial analysis 
we focused on the phosphatidylcholine metabolites since these exhibited significant sta-
tistical associations with HD disease progression scores. Using the previously published 
methodology of  Dharuri et al. [36] we extracted the genes from KEGG [43] and BioCyc 
[44] databases that corresponded to phosphatidylcholine related metabolic pathways. 
Consequently, we reanalyzed the previously published gene expression data from the 
same cohort, using the same linear model with the metabolomics dataset. We extracted 
the top 200 differentially expressed genes and compared them with phosphatidylcholine 
pathways related genes from the KEGG and BioCyc databases. We identified 8 genes 
that were present in both the differentially expressed gene list and the above databas-
es lists. These genes were ALOX5 (arachidonate 5-lipoxygenase), ALDH1B1 (aldehyde 
dehydrogenase 1 member 1), KMT2A (lysine specific methyltransferase 2A), MBOAT1 
(membrane bound O-acyltransferase DC1), MTRR (methionine synthase reductase), 
PISD (phosphatidylserine decarboxylase), PLB1 (phospholipase B1) and HADH (hy-
droxyacyl-CoA dehydrogenase). The correlation values of  each of  the 8 genes with the 
8 significant metabolites from our 4 group linear modeling analysis are represented in 
Figure 4. We observed that for the genes MBOAT1, PLB1, ALDH1B1 and MTRR the 
correlations with the majority of  the 8 metabolites were high (r > 0.6) while for the other 
4 genes the associations were average or poor. The highest associations were observed 
between the genes ALDH1B1, MTRR and PLB1 with phosphatidylcholines PC ae C.38:0, 
PC aa C36:5 and PC aa C38:6 (see Figure 5). Additional genes that were present both 
in the BioCyc and KEGG databases and our previous sequencing-based gene expression 
gene lists and for the amino acid serine were also NPL (N-acetylneuraminate pyruvate 
lyase), PGLYRP1 (peptidoglycan recognition protein 1) and TKTL1 (transketolase-like 
1). Finally, for the serine and threonine metabolites we could not identify any unique 
common genes. It should be noted however that the above phosphatidylcholine related 
gene ALDH1B1 was also present in our threonine KEGG reaction list and similarly PISD 
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and PLB1 were also present in our serine KEGG reaction list. To expand on the above 
findings, we performed a second analysis using the WikiPathways Web Service and all 
10 significant metabolites (8 phosphatidylcholines and 2 amino acids) from both of  the 
above metabolomics linear models, in order to investigate further connections between 
potential metabolomics and transcriptomic pathways. The metabolite-gene pathways 
with the highest overlap of  genes and metabolites we identified were glycerophospholipid 
biosynthesis (containing genes PLB1, PISD and Serine and 1,2-diacyl-sn-glycero-3-phos-
phocholine (1+)) and phase II conjugation (containing gene MTRR and serine and 
threonine), supporting the results from our first pathway analysis. All the overlapping 
pathways reported for the Wikipathways analysis can be seen in Supplementary File 6. 
Figure 4. Heatmap of  correlation values between gene expression levels and phosphati-
dylcholines metabolite concentrations. The selected genes shown here are genes identi-
fied using our previous gene expression data and that participate in phosphatidylcholine 
KEGG and BioCyc pathways and reactions. Phosphatidylcholines shown here are the 
statistically significant phosphatidylcholine metabolites identified from the 4 group lin-
ear modelling analysis. Color key represents absolute correlation values.
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Figure 5. Plots of  selected phosphatidylcholine metabolites versus their corresponding gene 
that participates in phosphatidylcholine pathways or reaction. The 3 plots represent the most 
highly correlated metabolite to gene pairs from the integration of  metabolites to gene expres-
sion data analysis. Different colored dots represent individual samples from each disease state 
group and brown lines represent loess fit lines.




The current study targeted approach of  the Biocrates technology has been successfully 
applied in many cohort studies [45-47].  Comparison of  this type of  data with data 
obtained from non-targeted platforms has shown strong positive correlations for me-
tabolites named for the same compounds. Furthermore such a comparison has shown 
that the results obtained are complementary and informative for future studies of  com-
prehensive metabolomic analyses with different platforms [48,49].Using a well-defined, 
UHDRS-based linear model, we discovered a total of  10 metabolites whose concentra-
tions showed significant associations with Huntington’s disease state and severity stages. 
Eight of  the 10 metabolites were phosphatidylcholines while the other two were the 
amino acids serine and threonine. These results are in agreement with the results of  
Tsang et al. that have reported a decrease of  phosphatidylcholine levels in frontal cor-
tex lipid extracts of  a 3-NP treated HD rat model [50]. Phosphatidylcholine is a major 
membrane phospholipid and has been shown to have a role in neuronal differentiation 
and cell fate determination [51]. In the past, oral administration of  lecithin and other 
choline containing dietary sources have been suggested as a replacement therapy for 
HD and as a potential substrate source for brain acetylcholine synthesis [52]. The cur-
rent study shows an increase of  serine and threonine in HD patients as shown from the 
HD versus controls linear modeling. Serine has an important role in the metabolism of  
purines and pyrimidines since it is the precursor of  several other amino acids. It is also 
a precursor to numerous other metabolites, including sphingolipids and folate, which is 
the principal donor of  one-carbon fragments in biosynthesis. As such, one explanation 
for the increased serine levels could be that in Huntington’s disease these amino acids are 
intended for the production of  phospholipids whose levels are decreasing with disease 
severity. Moreover, the D-serine amino acid isomer can act as a neuromodulator since 
it can activate NMDA receptors. NMDA receptors have been implicated in a range of  
processes including memory, learning and development and their excessive stimulation 
can be involved in a number of  neurodegenerative conditions including HD [53]. 
The second of  the two amino acids whose levels were altered in HD, threonine, is an es-
sential amino acid and together with serine constitute the only two proteinogenic amino 
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acids. Threonine can be converted to pyruvate while in an intermediate step it can un-
dergo thiolysis to produce acetyl-coA. In a less common pathway threonine can also be 
converted to a-ketobutyrate via serine dehydratase. It has been previously suggested that 
pyruvate can have a neuroprotective effect in neurological diseases by, among others, en-




 and having an anti-inflamma-
tory action [54]. Furthermore it has been shown that pyruvate administration can have a 
neuroprotective effect in a quinolinic acid rat model of  HD [55]. Additionally, the inabil-
ity of  the excess threonine to undergo thiolysis and produce acetyl-CoA could result in 
reduced energy production (Krebs cycle) as well as an insufficient synthesis of  acetylcho-
line. The increased levels of  threonine in the mutation carriers could therefore represent 
a compensatory mechanism in an attempt to produce more substrates for the generation 
of  the above neuroprotective molecules such as pyruvate and/or the inability of  the thre-
onine metabolizing enzymes to properly process the present levels of  this amino acid.
Using the pairwise combination of  all the individual metabolites we discovered a series 
of  metabolites ratios (mainly phosphatidylcholines) that changed gradually with disease 
severity. These consisted of  the increase of  inter acyl-alkyl-phosphatidylcholines ratios 
but also changes in the sphingomyelins to phosphatidylcholines ratios. Sphingomyelins 
are a group of  sphingolipids found in mammalian cell membranes and especially mem-
branes that surround nerve cell axons [56]. A decreased ratio of  sphingomyelins to lipids 
across disease stages could indicate an increased vulnerability and damage of  nerve cell 
axons. Even though the role of  sphingolipids and gangliosides in brain damage has been 
investigated since the 1970s [57-59] it is not until recently that strong evidence has been 
presented in support of  the role of  gangliosides and their biosynthetic genes in autophag-
ic and apoptotic signaling [60,61]. Additionally, the ratio of  arginine to carnitine me-
tabolites was among the top results for the two group (HD vs controls) metabolite pair 
analysis with modest p-gain values. Arginine is a non-essential amino acid that is also 
a precursor of  nitric oxide (NO) a molecule involved in neurotransmission and inflam-
mation, both of  which processes are thought to be deregulated in HD [62]. It has been 
previously postulated that increased dietary l-arginine could accelerate motor symptom 
and weight loss events in HD models, through changes in cerebral blood flow and the 
regulation of  NO and nitric oxide synthase [63,64]. Furthermore, it has been also shown 
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that arginine uptake by HD patients separated them in two distinct metabolic profile 
groups indicative of  a complex and idiomorphic function of  this molecule across differ-
ent individuals [65]. Since the levels of  arginine were already found higher in HD in the 
individual metabolite analysis, the increased arginine to carnitine ratio in HD patients 
could indicate an arginine-concomitant decrease in the levels, of  the antioxidant and lip-
id regulator molecule, of  carnitine. This is further supported by the study of  Cuturic et.al, 
who showed that catabolism and chronic anticonvulsant administration in HD institu-
tionalized patients predisposed to low serum carnitine and that supplementation with 
levocarnitine improved motor and cognitive measures in these patients [66].Finally apart 
from their potential roles in deregulated HD molecular pathways these ratios could also 
serve as potential biomarkers of  disease progression since by calculating individual me-
tabolite ratios the dataset variation is reduced and the biomarker robustness is increased.
Moreover, we integrated our previously published gene expression data with the cur-
rent metabolomics dataset from the same cohort. In specific by generating bioinformat-
ics workflow-based metabolite specific gene sets we identified a group of  8 genes that 
were decreased in phosphatidycholine metabolic pathways and also found deregulated 
in our HD patients. Three of  these transcriptomics deregulated genes (MTRR, PLB1 
and ALDH1B1) exhibited especially high correlation with specific diacyl and acyl-al-
kyl phosphatidylcholines that were downregulated in HD in the metabolomics dataset. 
More specifically, MTRR is involved in the proper function of  methionine synthase and 
folate metabolism [67,68]. Mutations in the MTRR gene are thought to be responsible 
for multiple disorders and especially those affected through the deregulation of  the folate 
cycle and homocysteine metabolism [69,70]. In the past, increased levels of  plasma total 
homocysteine have been found in HD patients and it has been hypothesized that these 
increased homocysteine levels are a contributing factor to neurodegeneration in these 
patients [71]. The second of  the three genes whose expression was highly correlated with 
metabolite levels, PLB1 is a membrane-associated phospholipase with phospholipase A2 
activity that exhibits preferential hydrolysis at the sn-2 position of  diacyl-phospholipids. 
A recent study by Fonteh et.al. and in Alzheimer’s disease patients cerebrospinal fluid 
has shown that a significant increase in this phospholipase A2 activity accompanies the 
glycerophospholipid decrease observed in late onset AD patients [72]. This is in agree-
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ment with our data since the levels of  PLB1 exhibited an inverse correlation with all 8 of  
the metabolites that were statistically significantly associated with HD progression. Thus 
in a similar fashion with the findings of  Fonteh et.al the increased PLB1 phospholipase 
A2 expression levels in our HD blood samples could be indicative of  perturbation of  
membrane structures with a concomitant disruption of  cellular transport and clearances 
processes as well as a resulting inflammation overactivation [73,74]. Finally, this inte-
grated “-omics” analysis showed that potential pathways affected from the deregulation 
of  the above genes and changed metabolite concentrations were glycerophospholipid 
biosynthesis, vitamin B12 and folate metabolism. It has been previously shown that low 
choline and folate levels are interrelated and that the de novo synthesis of  phospha-
tidycholine is insufficicent to maintain choline levels when the levels of  the previous 
two compounds are also low [75]. Low folate has been associated with cardiovascular 
disease, a pathology that also affects HD patients and according to some surveys is the 
leading cause of  death in patients [76,77]. The administration of  choline has been shown 
to reduce total plasma homocysteine levels [78], an indicative cardiovascular disease risk 
factor, while folate and vitamin B12 supplementation has been considered as an addi-
tional supplementation therapy for many neuropsychiatric disorders [79,80].
Novel findings from our study include the serum upregulation of  serine and threonine 
levels as well as the inverse association of  the levels of  a group of  8 phospatidylcholine 
metabolites with disease progression. The lower level of  these metabolites support the 
evidence found regarding altered lipid metabolism in neurodegenerative disorders as 
well as the use of  phosphatidylcholine as a potential therapeutic avenue [81-83]. The 
increased amino acid level findings are in partial agreement with an older study that also 
identified increased serine levels but instead in the Broadmann’s area 10 of  HD patients 
[84]. On the other hand, these results are in contrast with the findings of  a study by 
Gruber et.al. that reported decreased levels of  serine and 4 more amino acids in HD mu-
tation carriers, in plasma samples [85]. Previous studies by Mochel et.al. have identified 
valine, leucine and isoleucine metabolite levels to be decreased in plasma samples of  HD 
patients versus presymptomatic and control individuals [86,87]. We could not validate 
this finding in our serum samples using the Biocrates platform. A possible explanation 
for this limitation could be the different platforms and protocols that were used to mea-
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sure the metabolites. Additionally, the differences could be attributed to the different 
group sizes and the different UHDRS score thresholds that were used to differentiate be-
tween presymptomatic, early and mild HD patient groups. Another potential limitation 
or reason in regard to the disagreement of  some our results with previous studies could 
be that our study was performed using serum samples while the previous studies were 
performed in plasma. In specific, using the Biocrates platform employed in the current 
study it has been shown that serum exhibits higher sensitivity than plasma due to the 
fact that metabolite concentrations are generally higher in serum samples [88,89] . An 
additional limitation of  the study could be the potential effect of  drug treatment on the 
metabolomics profile of  the individuals used for the current study, which was not taken 
into account since this information was not available for all study participants (especial-
ly controls). Considering the great disease phenotypic variation and the different pro-
gression rates that characterize Huntington’s disease mutation carriers our results will 
require further validation and refinement in even larger groups before they are used in a 
clinical trial setting. Such additional validation experiments can reduce the intergroup 
metabolite concentration overlap and clearly define the concentration thresholds that 
can be used to distinguish between disease progression/stages. Finally, further research 
would have to be performed to determine if  the current metabolic changes are specific 
for Huntington’s disease or might also partly track changes in other similar neuromuscu-
lar disorders and could therefore have additional potential diagnostic applicability.
The present study is according to our knowledge the first study that uses a targeted metab-
olomics approach in peripheral blood serum samples and in such a large cohort of  HD 
patient peripheral blood samples and with so many pre-symptomatic patients. Obtaining 
a disease specific metabolomic profile of  HD could greatly improve our understanding 
of  the disease pathology. Additionally, these profiles can potentially be used for patient 
screening as well as drug safety and effectiveness assessment. This could allow for earlier 
diagnosis something which is very important for HD where disease progression rates 
and clinical evaluation scores can be highly variable. Serum samples can also be collected 
noninvasively allowing for longitudinal studies as well as their use both in the preclinical 
and clinical settings. Our findings combined with the reproducibility and standardization 
of  platforms such as the one used in this study demonstrates the potential of  metabolo-
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Supplementary File 2. Metabolite correlation heatmap. Color key represents correlation 
values (Red represents high correlation - Blue represents low correlation). Individual 
metabolite names are located at the bottom and at the right side of  the heatmap.
Supplementary File 5. 
Top 10 metabolite pair values from the association analysis of  metabolite pair ratios 
using a 2 group design matrix (controls vs all HDs) and a 4 group linear modelling de-
sign matrix (controls and 3 HD disease stages). The metabolites pairs have been sorted 
according to decreasing p-gain values, resulting from the p-values of  the metabolite pairs 
relative to the smaller of  the individual metabolite p-values. Concentration changes were 
obtained from the fitted data of  the metabolite pairs ratios using the full linear statisti-
cal model (see methods) and disease state and stage respectively as the main covariate.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































WP2740 Glycerophospholipid       biosynthesis 101
PLB1 - PISD – Serine - 1,2-dia-
cyl-sn-glycero-3-phosphocholine (1+)
WP1880 Phase II conjugation 139 MTRR - Serine - Threonine
WP1533 Vitamin B12 Metabolism 112 MTRR - Serine
WP2650 Arachidonic acid           metabolism 102
ALOX5 -  1,2-diacyl-sn-glycero-3-phos-
phocholine (1+)
WP1857 Metabolism of  water-solu-ble vitamins and cofactors  168 MTRR - Serine
WP2693 Metabolism of  amino acids and derivatives 358 MTRR - Serine
WP176 Folate metabolism 132 MTRR - Serine
WP2719 Fc gamma receptor depen-dent phagocytosis 79
MYO10 -  1,2-diacyl-sn-glycero-3-phos-
phocholine (1+)
WP15 Selenium Micronutrient Network 188 ALOX5 - Serine
Supplementary File 6. Metabolomics and transcriptomics overlap-
ping pathways reported from the Wikipathways analysis.








The aim of  my thesis was to study the suitability of  peripheral whole blood to identify 
disease pathology related events in HD patients. In Chapter 2 I explored the dynamic 
range of  next generation sequencing-based transcriptomics by depleting the overabun-
dant hemoglobin transcripts present in peripheral whole blood, which limit the dynamic 
range of  this experimental approach. In addition, I focused on technical aspects of  using 
whole blood as a tissue. This is particularly important considering the problems in re-
producibility and lack of  inter-study validation that previous HD studies have reported 
until now [1]. In Chapters 3 and 4 I performed cross sectional transcriptomics and me-
tabolomics studies using samples from the same cohort of  patients. The experiments 
performed were based on the well described notion that the expanded mutant huntingtin 
protein causes both genome wide transcriptional deregulation and metabolic dysfunc-
tion and failure in energy metabolism. The aim was to discover novel transcriptomic 
and metabolomic blood biomarkers of  disease progression, validate previous ones and 
to identify novel or elucidate previous molecular pathways perturbed in HD. I did this by 
analyzing whole blood with state of  the art technologies such as Illumina RNA-seq gene 
expression tag profiling and the highly standardized tandem mass spectrometry-based 
metabolomics platform of  Biocrates. Subsequently we examined whether these technol-
ogies can produce useful results for disease stage and disease pathology event identifica-
tion. Finally, I investigated if  the results from the two different omics platforms could be 
combined as part of  a systems biology approach that could provide further depth and an 
additional layer of  disease knowledge relative to those that the individual study results 
could offer.
5.1.1 Globin Reduction Findings
In Chapter 2 I examined the effect of  depleting peripheral whole blood of  its highly 
abundant, hemoglobin transcripts (hemoglobin alpha and beta) and that constitute the 
majority of  transcripts per sample library size during next generation sequencing (NGS) 
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transcriptional profiling. I compared gene expression in 6 hemoglobin reduced whole 
blood mRNA samples with their 6 non-reduced counterparts. The gene expression anal-
ysis of  the non-reduced samples showed that hemoglobin transcripts (α and β) ranged 
from 52-76 % of  the total transcript population while the residual mRNAs constituted, 
on average, only 40% of  the samples’ total number of  transcripts. However, genome-wide 
gene expression profiling studies in blood aim mainly at studying this residual popula-
tion, made up of  the comprehensive set of  leukocyte transcripts, rather than studying 
events in the non-nucleated mature erythrocytes. This is because, apart from providing 
potential biomarkers, the leukocyte mRNAs can also reflect possible functional aspects 
of  disease pathology or highlight disease modifiers.
Our results showed that depletion of  the hemoglobin transcripts can provide additional 
sequencing reads for the remaining blood transcripts. I found that approximately 54% 
of  the total number of  genes discovered were significantly overexpressed in the globin 
reduced samples at a false discovery rate of  1%. On the other hand, only around 4 tran-
scripts of  other genes per mille (87/21633) were inadvertently reduced in the treated 
samples. This indicates that the potentially unwanted side effects of  the globin depletion 
on gene discovery rate is very small. Moreover, we could not identify sequence specif-
ic properties (using BLASTN) particular to the few genes that were lost which would 
robustly explain the systematic loss of  these genes. By studying the composition of  the 
genes present in low copy numbers, I discovered that the functional biotype of  these 
genes included cell surface receptors, signal transduction proteins and G-protein coupled 
receptors. Moreover, the relative percentage of  low abundance genes was higher for gene 
classes like processed transcripts, lincRNAs and miscellaneous RNAs, when compared 
to the more typical gene class of  protein coding transcripts. It has been postulated that 
transcripts that are currently considered as non-coding or non-functional could also be 
called “currently unannotated”. Indeed, when the function of  these transcripts is dis-
covered this will also have implications to the already discovered protein coding tran-
script functions [2]. Low abundance genes such as the ones reported above can be also 
important for HD and other neurodegenerative diseases since they are often found to be 
differentially regulated in gene expression studies. Thus, it is vital that their levels can be 
measured with high accuracy and at sufficient depth. However, analytical protocols and 
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techniques have not been sufficiently developed for these genes to be easily quantified. 
This means that these are often overlooked and substituted by other candidate transcripts 
that are more highly expressed and easily detected. For example, Labadorf  et al., using 
RNA sequence analysis of  human brain samples, showed that the most significantly 
differentially expressed genes in HD were Hox and other homeotic genes [3]. However, 
they also showed that the relative abundance of  almost all of  those Hox genes was low, 
around 10 % or less of  the median normalized tag count average of  all genes. Therefore, 
even though the levels of  such genes could be strongly associated with disease it would 
not be possible to routinely and robustly quantify (or even detect) them unless a very 
high sequencing depth is employed. The latter situation is complicated even more when 
studies are performed in a tissue such as blood that is dominated by a few overabundant 
globin transcripts. For this reason and in order to determine how the hemoglobin over-
abundance effects the detection of  all the transcripts/genes present in blood I performed 
an in-silico analysis of  gene expression sequencing depth versus the total number of  
detectable transcripts. This analysis showed that for a given number of  detected genes 
(in this case approx. 13.000 genes) non-globin reduced samples require almost twice as 
many sequencing reads to detect the same number of  genes found in globin depleted 
samples. As NGS costs continuously drop, sequencing cost savings could best be used 
to increase the study sample size, the within study sample replication numbers or to per-
form separate replication experiments.
Finally, at the end of  the second chapter I demonstrated that for the same number of  
sequencing reads a higher number of  genes can be detected in globin reduced samples 
even at sequencing depths as high as 60 million reads. This means that even a great and 
costly increase in sequencing depth of  blood samples would still be insufficient to detect 
all the genes present in these samples when hemoglobin transcripts are present (at 60 
million reads). Additionally, the fact that even at such great sequencing depths not all the 
genes or transcripts are identified can cause inaccuracies in gene expression studies. For 
example, studies claiming that a specific set of  genes is exclusively expressed (differential 
expression) in a disease state, have to provide strong evidence that the transcriptome of  
interest has been extensively sequenced and have sufficient statistical power and sample 
size [4]. Even though advanced statistical methods have been designed to estimate and 
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normalize the sample library sizes; such as the “Trimmed Mean of  M-values” (TMM), 
these methods are at best very good approximations of  the actual library sizes and are 
applicable only under the condition that exactly the same amount of  starting RNA has 
been used [5]. Moreover, even the most current and widely used sequencing-based gene 
expression algorithms, such as edgeR [6], estimate the sample gene frequencies based 
on the total number of  genes found in the sample. Therefore, if  a relatively high number 
of  low abundance genes, like transcription factors or others known to be deregulated 
in HD, are not robustly sequenced (or not detected at all), these genes will have a low 
chance to be correctly estimated and appropriately associated with disease state. Conse-
quently, globin reduced samples, yielding twice as many genes than their non-reduced 
counterparts, further contribute to obtaining a better representation of  the transcriptome 
and a more accurate estimation of  low abundance transcripts. This is of  the utmost 
importance for gene expression studies and transcriptional biomarker studies, since the 
transcriptional capacity of  mammalian genomes, in contrast to lower level eukaryotes, is 
immense - consisting of  thousands of  genes and numerous isoforms that are transcribed 
in an interleaved fashion across the whole genome [2,7].
5.1.2 DeepSAGE gene expression findings
In the second chapter of  this thesis I used peripheral whole blood samples of  HD pa-
tients and controls to perform a cross sectional genome wide gene expression profiling 
study. Until recently gene expression profiling studies were performed using hybridiza-
tion-fluorescence-based microarrays. However, these platforms suffer from several lim-
itations like cross-hybridization, low sensitivity and exclusive focus on the genes present 
on the array. This is not the case with NGS-based genome-wide transcriptional profiling. 
In addition, this approach provides better sensitivity, discovers novel transcripts and bet-
ter quantifies low and high abundance transcripts. We collected 150 patient and control 
samples in a systematic and reproducible manner using Paxgene tubes, which preserve 
the level and quality of  the RNA samples at venipuncture. Since it was not feasible to 
use the globin reduction approach described above in our current HD cohort study, we 
used a sequencing protocol (DeepSAGE tag profiling) that only sequences a small part 
(tag) of  the 3 ‘UTR, which uniquely characterizes each mRNA transcript. Thus, we 
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could achieve a much higher sequencing depth than with standard RNAseq. To identi-
fy transcriptomic changes that would function as potential disease progression/severity 
biomarkers we performed a linear modeling analysis using as, our main covariate the 
UHDRS total motor score (TMS) and which describes muscle and motor degeneration 
in HD patients. Despite the fact that TMS, is characterized interrater variability and 
other disadvantages, we were the first to replicate results for several genes reported as 
potential blood biomarkers by previous HD gene expression studies. Furthermore, when 
we performed the linear modelling analysis using the total functional capacity score as 
an alternative main covariate, a large proportion of  the top differentially expressed genes 
(≈ 60%) were the same as the ones discovered by the total motor score analysis reflect-
ing the good correlation between TMS and TFC in HD patients. Moreover, we used a 
high-throughput nanoliter RT-qPCR platform to validate a selected number of  20 genes 
in the original discovery cohort and in a second independent cohort. We were able to 
validate 5 of  the 20 genes that were significantly associated with TMS in both cohorts. 
Furthermore, we produced a gene expression based algorithm using the “Lasso” ap-
proach (Least Absolute Shrinkage and Selection Operator) that could be used to predict 
the motor symptom progression in patients. This uses the expression levels of  a specific 
set of  genes, age and gender. This analysis showed that gene expression could be used 
with good results to predict motor symptom pathology, especially for the earlier stage 
symptomatic patients. For the later stage patients (higher TMS) the scores predicted 
by the blood gene expression were mostly significantly lower than their corresponding 
clinical motor scores. One reason for this could be the reported plateau effect of  disease 
progression and specifically of  chorea in more advanced HD patients  [8]. We note that 
this gene expression-based motor score predicting formula may well reflect, besides pre-
vious neurodegeneration, also degenerative events from other tissues that blood comes 
into contact with. This has been previously also suggested by Hodges et.al. [9] who 
noted as a potential limitation in HD brain studies that changes in susceptible cells are 
inextricably mixed with effects of  previous neurodegeneration. For our blood study this 
could also explain why the motor score algorithm predicted lower motor scores for the 
most advanced patients. Furthermore, this analysis demonstrated that even genes (such 
as ARL4C – see Chapter 2.3.3), which do not achieve statistical significance in statistical 
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or validation analyses may still play a role in a more accurate representation of  disease 
progression. Here we have used the “Lasso” approach to show that a panel of  genes can 
be trained to describe disease stage or severity. Similar to using a combination of  differ-
ent types of  biomarkers (molecular, imaging etc.) to better define overall disease progres-
sion in a multifaceted disease like HD, the combined use of  several blood biomarkers 
may best describe disease progression and/or severity. In our dataset, the TFC score and 
the TMS score exhibited high correlation for most, but not all HD patients. This could be 
caused by the fact that some HD patients exhibit severe psychiatric symptoms affecting 
everyday independent functioning at an early stage, while developing motor symptoms 
only later in live. For these patients, most likely a different profile of  gene expression 
biomarkers will best reflect their progression. Thus, different groups of  gene expression 
biomarkers could be formed by a core of  robust and/or highly expressed, statistically 
significant genes, but also contain other genes which represent more phenotype-specific 
information. 
Finally, while there is an urgent need for the identification of  panels of  biomarkers with 
high performance characteristics such as robust expression and sensitivity, knowledge 
about the biological functions and pathway modules that these biomarkers are involved 
in will also be very important. Such functional information will provide further speci-
ficity and clues about the mode of  action and effectivity of  potential therapeutic agents. 
For this reason, I performed different pathway analyses and identified disease related 
biological terms and pathways. These can be used to choose biologically relevant genes 
that will be the most appropriate for chosen therapeutic approaches and the most infor-
mative regarding the underlying processes that are altered during disease progression.
5.1.3 Metabolomics and integration with transcriptomics find-
ings.
In recent years, several systems biology studies have combined the use of  genomics, 
transcriptomics and proteomics data to identify biomarkers for therapeutic clinical trials. 
The field of  metabolomics has also made great strides to extend such multidimensional 
system-level approaches and produced some promising results in the last decade [10,11]. 
Chapter 5             
180
However, few metabolomics studies have been performed in comparison with DNA, 
RNA and protein studies, the three biological classes following the central dogma of  bi-
ology. In our study, we applied targeted metabolomics in serum samples of  HD patients 
and controls. This targeted approach is important given the heterogeneity of  the periph-
eral whole blood, which contains several overabundant proteins that hamper detection 
and identification of  the less abundant metabolites [12]. We could identify a total of  
10 metabolites that either separated controls from mutation carriers or tracked disease 
progression across clearly defined disease stages. Our results are in agreement with the 
results of  Tsang et al. who showed phosphatidylcholine to be decreased but in the frontal 
cortex of  the 3-NP HD rat model. [13]. Some of  our results have been partially validated 
at the individual metabolite level by Cheng et al. who, similarly using targeted metabolo-
mics, also reported phosphatidylcholine acyl alkyl C:36 (PC ae C36:0) to be deregulated 
in the blood plasma fraction of  HD patients [14]. The fact that one of  the biomarkers 
identified in the current thesis could be validated in an independent cohort and in a dif-
ferent laboratory setting warrants additional validation experiments to identify, in detail, 
the extent to which this phosphatidylcholine level can track disease progression. 
Finally, we combined our previously published gene expression data from the same co-
hort with the metabolomics data, to explore what could cause the concentrations of  
these metabolites to change in the patients’ serum. To perform the above integration, 
we used correlation analysis, workflow based exploitation of  databases and open pub-
lic platforms like WikiPathways. Approaches like WikiPathways enable researchers to 
take advantage of  the expert knowledge of  their colleagues, who continuously update, 
curate and enrich biological pathway information based on novel information from their 
research. Our analyses identified a set of  8 genes, 4 of  which exhibited high correlation 
with most of  the metabolites changed in disease. The most prominent biological terms 
that were associated with these highly-correlated genes were deregulation of  the folate 
cycle and homocysteine metabolism (MTRR gene) but also potential deregulation of  
phospholipase activity – based on the levels of  PLB1 gene. These results are supported 
by several HD metabolomics papers concerning the deregulation of  genes and metabo-
lites involved in antioxidant defenses and neurodegeneration. Notably, Andrich et al. re-
ported increased plasma total homocysteine in treated HD patients and two further stud-
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ies reported deregulation of  enzymes involved in the regulation of  the levels of  cysteine 
[15-17]. The exact mechanism by which the levels of  these amino acids and expressed 
genes are connected is not clear, but our results stress the need for further studies. Finally, 
our findings underscore the value of  such system-biology approaches to enhance our 
knowledge on disease pathology. Genes such as the ones found by the above integrative 
approaches could have easily been overlooked and replaced with slightly more robust 
or more significant genes which might nonetheless be less meaningful biologically, dis-
ease specific or functionally relevant. Indeed, small fold changes in gene expression or 
metabolite concentration levels identified by the previous individual studies can become 
far more significant when the data from the separate experiments are aggregated into a 
single multidimensional biological readout, highlighting much more dynamic shifts in 
the overall flux through relevant biological pathways. 
5.2 Limitations and challenges
The advent of  next generation and high throughput “-omics” technologies in the re-
cent years has provided the unique opportunity to generate a plethora of  data about 
patient genomic variants, mRNA and miRNA expression changes as well as the concen-
tration levels of  proteins and metabolites in various patient tissues. Nonetheless, despite 
these unique opportunities the clinical utility is still limited compared to the volume 
and breadth of  the originally produced data. Several study design limitations as well as 
technical and biological challenges hinder the fields of  personalized genomics and sys-
tems biology from achieving its goals and obtaining robust, reproducible results. In the 
following paragraphs, such limitations relative to the studies published in this thesis are 
discussed and critically analyzed.
The use of  peripheral blood for the discovery of  biomarkers and surrogate pathologies 
and endpoints has proven to be a double-edged sword in HD. Despite the advantages of  
this tissue, researchers have not yet been able to fully harness the potential of  peripheral 
blood as a source of  clinical biomarkers. This is mainly due to the fact the different blood 
cell types are also sensitive to numerous preanalytical aspects of  the study design, such 
as circadian rhythm and time of  sample collection, the use of  different sample collection 
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and storage protocols, patient nutritional status or other lifestyle factors that can affect 
cellular expression levels, such as medication, alcohol consumption or smoking. There-
fore, even though the cohort used in our study was subjected to very strict age and gender 
stratification, the specificity of  the study would have benefited from additional informa-
tion regarding sample collection time, fasting state and additional information regarding 
medication and lifestyle. The Paxgene tube collection method preserves the samples as 
whole blood lysates, and as discussed earlier this results in the overabundance of  hemo-
globin transcripts which in turn limits the experimental dynamic range and consequently 
the statistical power of  the results. Even if  a depletion approach as described in Chapter 
2 is followed, one needs to consider additional variation and reproducibility issues result-
ing from hemoglobin reduction, like decreased RNA quality and increased inter-sam-
ple variability, but also whether post-depletion sample concentrations will be adequate 
for secondary validation studies. However, considering the continuous development of  
increasingly sensitive state of  the art platforms, enabling the progressive lowering of  
required sample amounts, it is this author’s opinion that RNA quality is the more crit-
ical factor. It is our experience that whole blood RNA extracts exhibit lower post RNA 
purification quality, notably relative to cell lysates, and it is well known that RNA quality 
influences gene expression levels detectable. Even though in Chapter 2 we showed that 
RNA quality degradation of  the depletion protocol is relatively small, this decrease can 
still cause the exclusion of  a good number of  available samples in, subsequent quality 
control because of  missing data, notably when their initial quality is already low. 
Our metabolomics approach had as a unique and important characteristic that large 
numbers of  reproducibly collected HD samples were analyzed by a well-known and 
standardized targeted metabolomics platform. Furthermore, linking metabolomics with 
state of  the art gene expression data showed promising correlations between genes and 
metabolites, both at the functional and the expression level. Metabolites can act both as 
feed forward and feedback reaction modulators and our linear modeling and gene ex-
pression correlation analyses may reveal only a limited amount of  the underlying disease 
pathology. Furthermore, our study could not quantify metabolites whose concentration 
levels were below the lower limit of  quantification and/or the limit of  detection. The 
metabolite group below the limit of  detection were mostly carnitines. Nonetheless, from 
                     Discussion
183
5
previous studies it is likely that the vast majority of  the undetected metabolites is due to 
the tissue type (serum) and platform used rather than the absence of  the metabolites in 
the disease stage [18]. Finally, results from cross-sectional studies are sometimes limited 
because they only capture a snapshot of  the patients’ biological fluids during a single 
sampling point, a static representation of  the patients’ disease stage at the time of  veni-
puncture. Thus, two patients that share an almost identical biofluid profile at the time 
of  blood sampling might have a very different disease course previous to this point. This 
applies particularly well for HD since it is known that the disease manifests itself  though 
a multitude of  symptoms and with highly variable progression rates. Therefore, such 
studies cannot be used alone to derive meaningful therapeutic endpoints. Even though 
they can provide important knowledge about disease bio-pathology, any conclusion(s) 
emerging from such studies will require additional validation in longitudinal studies. 
5.3 Future directions 
The future of  biomarker discovery will arguably revolve around the use of  systems bi-
ology approaches, integrating genomics, transcriptomics, proteomics and metabolomics 
to monitor human health and disease as well as the efficacy of  therapeutic strategies. 
Such multi-omics approaches will benefit from further developments in analytical and/
or clinical technologies which provide observable characteristics – known as endophe-
notypes - to extract highly accurate and informative molecular biomarkers.  Potential 
endophenotypes are for instance brain atrophy scores produced by MRI experiments, 
psychopathology and rates of  cognitive decline. The combination of  these disparate data 
types with molecular measurements will require the collaboration of  many disciplines to 
interconnect the data generated by clinicians and basic investigators. Independently of  
which type of  biomarker might become more easily adopted or be the most informative, 
there is a widespread consensus that for a multifaceted disease like HD a single biomark-
er will not be sufficient. Rather, a battery of  biomarkers will be required to fully charac-
terize the disease progression and evaluate the therapeutic potential of  future treatments. 
In the following paragraphs, additional future directions are described, both based on the 
studies performed in this thesis and more generalized future directions of  blood based 
study designs based on information from the HD research community and field experts.
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For personalized genomics and systems biology to make the transition from future aims 
to current and realistic tools in the hands of  researchers, the simultaneous processing of  
a much larger number of  samples is required, offering greater statistical and discovery 
power. The collection of  enough informative samples can be achieved either through a 
centralized approach, where all samples are preprocessed together, or by meta-analysis 
of  data collected in several smaller decentralized laboratories. Irrespective of  which of  
the last of  the two approaches proves the most efficient, for the results to be meaningful 
and informative, preprocessing variation needs to be kept to an absolute minimum. It 
has been demonstrated by Schurman et al. that several technical and experimental vari-
ation factors such as technical platform parameters, sample collection parameters and 
batch wise RNA isolation and amplification influence the gene expression results.
Therefore, considering the gene expression protocol used in this study we emphasize the 
need for simpler and easier to perform protocols to avoid batch effects. Even though the 
DeepSAGE protocol employed in the current study offers unique advantages such as 
increased sequencing depth and improved dynamic range, the subsequent use of  restric-
tion enzyme and polymerase reactions to produce the required sequencing “tags” make 
it a demanding and laborious protocol. As the NGS platforms evolve we may expect that 
sample processing and sequencing construct generation protocols will also be further 
optimized i.e. by sample processing in a 96-well format which is already being applied. 
These improvements allow for the easy and simultaneous processing of  a larger number 
of  samples, eliminating difficult to spot batch effects. Using more, and more uniformly 
treated samples facilitates the greater statistical power needed in a multifaceted, high-
ly variable disease like HD and eliminate inter-lab assay performance and variability. 
In addition to the use of  uniform sample collection, storage and analytical protocols, 
further efforts should be intensely advocated to select a narrower group of  high quality 
clinical markers and progression scores that can best define disease pathology. Initiatives 
to this end are being taken by well-respected researchers and authorities in the HD field 
such as the TRACK-HD consortium [19]. These carefully chosen scores and grades can 
then be more widely and more uniformly adopted as potential covariates in the various 
statistical analyses employed by the different studies and research groups. This will assist 
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in reducing the gap in reproducibility and common findings between various studies, 
which even though similar in nature, nonetheless have used very different cohort strat-
ification designs or clinical sub-scores to interpret the biological data produced. This 
would respond to the goal set by the European Huntington’s Disease Network (EHDN) 
to standardize clinical scores. Technologies such as flow sorting and cytometry, that cap-
ture and sequence the transcriptome of  a specific number and type of  blood cell types, 
will provide more detailed blood transcriptome data and should overcome the hurdles 
posed by overabundant hemoglobin transcripts. In addition, more advanced statistical 
models could be applied to identify additional perturbed pathways since disease relevant 
associations between metabolite and gene expression are not always explained by 1:1 
stoichiometric relationships. One such example of  additional bioinformatics approaches 
is the use of  artificial neural networks (AANs). These are inspired by biological neural 
networks and employ tunable numerical parameters or weights which can be trained on 
the data and used to approximate non-linear relationships between an input and an out-
put molecule or disease state [20]. Finally, even though targeted and untargeted metab-
olomics approaches have their own limitations and advantages, in the future they could 
both be used in a complementary manner to reveal additional and more comprehensive 
metabolite disturbances.
5.4 Epilogue
The role of  blood as a pathology and biomarker discovery tissue in HD and other neu-
rological disorders has been the topic of  many heated debates and stalemated scientific 
discussions. Irrespective of  the extent to which blood and its biomarkers will be prov-
en to associate with central HD brain pathology, it is this author’s opinion that in the 
future, blood biomarkers will irrefutably have an important role in disease progression 
and therapeutic monitoring. Even if  these blood indices are more distal and less specific 
than more proximal biomarkers, this drawback is more than cancelled by the ability 
to repeatedly and continuously collect disease signature measurements, in an easy and 
reproducible manner, across a large number of  individuals, providing an otherwise un-
obtainable sensitivity for the monitoring of  clinical and therapeutic trials. Considering 
the multiplicity of  HD pathology and its symptoms it is already well established and 
Chapter 5             
186
widely accepted that blood alone will not be sufficient to describe all disease aspects. 
Therefore, in such a context, the high sensitivity measurements of  a biomarker obtained 
in a casual repeated fashion can overshadow the potential loss in specificity. Although 
continuous technological improvements of  platforms and protocols will provide further 
breakthroughs, a great deal can be gained from additional standardization of  sample 
collection/storage and the communal adoption of  the same standardized clinical scores 
and endophenotypes for the inter-laboratory statistical analyses of  extracted data. The 
latter will be especially useful in inductive biomarker identification approaches where 
the unbiased identification of  a large number of  molecules is performed through the 
use of  state of  the art high throughput technologies like the ones described in this thesis 
To truly estimate whether blood can provide the required disease progression and ther-
apeutic efficacy information, it is necessary to account for additional sources that con-
tribute to biological variation in this tissue. This thesis has analyzed several technical 
and experimental tissue specific sources of  variation. However, other genetic regulatory 
sources of  human gene expression variation could have effects on interpreting expression 
differences, such as epigenetic regulation or expression quantitative trait loci (eQTLs). 
For instance, recently von Schimmelmann et al. showed that deficiency of  Polycomb re-
pressive complex 2 (PRC2), an epigenetic gene regulator, causes transcriptional changes 
and a temporal type of  PRC2 dependent gene de-repression that leads to a progressive 
and fatal neurodegeneration reminiscent of  HD [21]. Furthermore, Sudarsanam et al. 
showed that variations in genomic regulatory features such as quantitative trait nucle-
otides (QTNs) found in Saccharomyces cerevisiae transcription factor genes, produced 
variation in gene expression (49%) which however was not predictive of  the phenotypic 
variation (98% sporulation efficiency) that could be explained by the QTNs [22]. Inte-
grative genomic and QTL mapping approaches in Arabidopsis lines have shown that 
genetic variation in gene expression is not always evidenced by phenotypic variation 
[23].  Finally, human cortical gene expression analysis has also shown that inter-individ-
ual cortical expression was correlated with genome wide genotypic variation. As shown 
by the above studies in Saccharomyces and Arabidopsis, phenotypic changes are often 
masked or delayed by transcription network buffering interactions. All these studies lead 
to the conclusion that assessing the impact of  the individual, natural and genome wide 
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expression variation across different tissues will be an important requirement for cor-
rectly defining pathological thresholds or biomarker level changes in disease. Such ex-
pression variations or buffering networks need to be better studied before we attempt to 
correlate tissue gene expressions signatures such as those between blood and brain across 
individuals with a different genotypic background. This kind of  information will go hand 
in hand with disease specific genomic studies such as the one recently performed by the 
GeM-HD consortium that has identified genetic modifiers of  HD and improve our un-
derstanding of  genome to phenome correlates. All of  these considerations emphasize 
the need to further promote the design of  multi-level systems biology approaches since 
only the detailed mapping of  all disease processes, from the genome to the metabolome, 
will be the most effective for developing therapeutic insights. Individualized disease spe-
cific information will not only allow for the finer stratification of  patient cohorts but will 
also allow us to better interpret the results identified by the individual segments of  the 
central dogma of  molecular biology and produce a more personally tailored, accurate 
and effective therapeutic approach. Increasing evidence has led to the suggestion that 
Huntington’s disease could be an “unfortunate by-product” of  the evolution toward a 
highly-sophisticated brain which required an ever-lengthening HD gene [24]. However, 
we have yet to explain why after a certain number of  CAG repeats the gene product 
becomes toxic and what mechanisms allow carriers to (variably) not develop symptoms. 
Therefore, the identification of  genetic or environmental features that will provide or 
strengthen phenotypic buffering might not only protect present mutation carriers but 
could also protect non-carriers from a future evolutionary perishing.
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Summary
Even though Huntington’s disease (HD) and its most prominent symptoms were de-
scribed in the middle of  the 19th century, it was not until the last decades of  the 20th 
century that a systematic analysis of  the biology and genetics of  the disease started. 
Great efforts by the scientific and patient community have raised disease awareness, re-
duced the disease stigma, allowed for a better and earlier recognition of  potential symp-
toms and offered perspective for therapy development. The disease is known to exhibit 
geographic prevalence differences. The most recent data suggest that disease prevalence 
in Australia, North America and Western Europe has increased by approximately 15-
20 % per decade for the second half  of  the 20th century. This increase accentuates the 
need to care for these patients and to identify symptomatic treatments and therapeutic 
approaches for the disease.
The work described in this thesis presents part of  a framework that can be used to extract 
detailed disease biological information from peripheral tissue. This framework is based 
on the central dogma of  biology “DNA to RNA to protein” and on a systems biology 
approach that aims to produce synergetic data whose disease pathological, prognostic 
and predictive value is greater than the sum of  the individual experiment results. HD 
patients are often characterized by a multifaceted clinical profile, consisting of  several 
symptoms and variable disease progression rates. Therefore, a systems approach such as 
the one described above is expected to be the most effective in identifying potential treat-
ments and predictive biomarkers that will be most informative for the different patient 
subpopulations. 
In Chapter 1, a detailed report of  the disease background and symptoms is provided 
as well as current potential therapeutic approaches. In the last part of  the chapter a 
thorough description is presented of  the ideal properties of  a disease biomarker. These 
properties are discussed in the context of  the idiomorphic character of  HD symptoms 
and, most importantly, the development of  a blood biomarker reflecting brain pathology.
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In Chapter 2 we investigate the depletion of  the overabundant hemoglobin transcripts 
from next generation sequencing (NGS) gene expression peripheral blood samples. Even 
though technological breakthroughs such as NGS offer increased sensitivity and dynam-
ic range the disproportionate number of  hemoglobins in whole blood samples reduces 
the sequencing depth potential and the identification of  the less abundant blood tran-
scripts. We showed that by removing the hemoglobins, other types of  transcripts such 
as lincRNAs, misc-RNAs and processed transcripts are increasingly and more reliably 
detected. To our knowledge this study was the first to describe the effects of  such a de-
pletion process on RNA sequencing data and especially in human blood samples. The 
various low abundance transcripts often play potentially important roles in disease in 
general which is also the case for Huntington’s disease [1]. 
Chapter 3 describes the results of  our whole genome gene expression profiling study em-
ploying NGS in peripheral whole blood samples. To date, our study constitutes the larg-
est peripheral whole blood gene expression study; including such a substantial number 
of  pre-symptomatic patients. Additionally, this study was the first HD study to have used 
next generation sequencing-based gene expression profiling, in contrast to hybridization 
microarrays which were previously the most commonly used platform. Our results con-
firmed for the first time blood gene expression changes found in previous studies, thus 
highlighting the potential of  NGS to obtain disease relevant biomarkers. We showed that 
by employing appropriate statistical approaches, genes other than the most statistically 
significant ones can be used to establish disease progression biomarker panels. Such 
biomarker panels can consist of  a combination of  genes which, in addition to mere 
statistical significance, may provide complementary disease-specific information. These 
panels can potentially be refined to best reflect the pathological state in the different 
severity groups.
In Chapter 4 we performed an advanced integration of  high throughput, large cohort 
data from blood and from more than one biological data classes. We integrated our 
targeted metabolomics results with our previously described NGS transcriptomics data 
from the same patients and controls. Metabolomics can reflect changes occurring down-
stream of  the gene expression level and its deregulation that takes place in HD. Further-
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more, targeted metabolomics has the advantage of  enabling robust, reproducible and 
repeated measuring of  the discovered changes in potential future longitudinal studies. 
By this multidisciplinary approach and employing community-driven bioinformatics re-
search tools, we could link the changes in the HD patients’ metabolite concentrations 
with specific subsets of  the top deregulated genes of  our gene expression dataset. Our 
integrative effort constitutes one of  the first multi-level “omics” approaches, in the future 
to be enriched by additional biological data classes, thus providing a much-needed, more 
holistic description of  HD disease pathology.
Finally, in Chapter 5 a critical evaluation was given of  all the data produced and the 
conclusions drawn in the previous chapters. The knowledge gained by each of  the above 
phases was assessed in the context of  the novelty and applicability of  the methodological 
approaches and platforms employed. In the penultimate part of  this chapter the limita-
tions of  each of  the above experiments were scrutinized with respect to the inherent 
technical limitations of  the study designs and the analytic tools used. Finally, potential 
future directions and advancements associated with the study design, analytical compo-
nents and bioinformatics tools used in each individual study were outlined. 
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Samenvatting
Ook al werd de ziekte van Huntington (ZvH) met de belangrijkste symptomen reeds 
beschreven in het midden van de 19e eeuw, het duurde tot de laatste decennia van de 20e 
eeuw voor er een systematische analyse van de onderliggende biologie en genetica tot 
stand kwam. Enorme inspanningen van wetenschappers, artsen en patiënten hebben er- 
voor gezorgd dat de bekendheid van de ziekte is toegenomen, het taboe rond de ziekte is 
verminderd, er een betere en vroegere herkenning van potentiële symptomen kwam, en 
er nieuwe therapieën ontwikkeld werden. Bekend is dat de prevalentie van de ZvH kan 
verschillen per geografische locatie en recente data suggereren dat de prevalentie van de 
ZvH in Australië, Noord Amerika en West Europa over de laatste helft van de 20e eeuw 
is toegenomen met 15-20% per decennium. Deze toename in prevalentie benadrukt nog 
eens de noodzaak voor goede zorg voor deze patiënten en om symptomatische behan- 
delingsmethodes te ontwikkelen en nieuwe therapeutische toepassingen.
Het werk beschreven in dit proefschrift vertegenwoordigt een onderdeel van een kader 
dat gebruikt kan worden om ziekte specifieke biologische informatie te halen uit perifeer 
weefsel. Dit kader is gebaseerd op het centrale dogma uit de biologie DNA -> RNA -> 
eiwit en een systeembiologische benadering die tot doel heeft om synergistische data 
te produceren waarbij de som van de pathologische en voorspellende waardes meer is 
dan die van de resultaten van de individuele experimenten. Sinds patiënten met de ZvH 
vaak een veelzijdig klinisch profiel hebben dat bestaat uit verschillende symptomen en 
een variabele progressie van de ziekte, ligt het voor de hand dat een benadering zoals 
hierboven beschreven effectiever zal zijn in het identificeren van potentiële therapieën en 
voorspellende biomarkers die het beste passen bij de verschillende patiëntenpopulaties.
In hoofdstuk 1 wordt een gedetailleerde beschrijving gegeven van de symptomen van 
de ZvH en de huidige potentiële therapieën. Het laatste deel van dit hoofdstuk geeft 
een beschrijving van hoe de ideale ziekte-biomarker eruit zou moeten zien. Deze ei-
genschappen worden besproken in de context van het idiomorfe karakter van de ZvH 




nodig zijn zodat een bloed-biomarker een weerspiegeling is van de pathologie die zich 
afspeelt in de hersenen.
In hoofdstuk 2 onderzoeken we de depletie van de hoog tot expressie komende hemo-
glo- bine transcripten op de next generation sequencing genexpressieanalyse van bloed. 
Voor zover we weten was ons artikel het eerste welke het effect beschreef  van deze de-
pletie op RNA sequencing data en specifiek in humane bloedmonsters. Ook al leveren 
technologische ontwikkelingen zoals next generation sequencing een toegenomen sensi-
tiviteit en dynamisch bereik, de onevenredig hoge expressie van hemoglobines in totaal 
bloed vermindert het sequencing potentieel en de identificatie van transcripten die laag 
tot ex- pressie komen. We hebben aangetoond dat door het verwijderen van de hemo-
globines, andere transcripten zoals lincRNAs, miscRNAs en processed transcripten in 
meerdere mate en consequenter gedetecteerd kunnen worden. Dit soort transcripten 
die laag tot expressie komen spelen vaak een belangrijke rol in ziekten in het algemeen 
maar ook specifiek in de ZvH [1]. Dus laten we zien dat reductie van hemoglobine 
transcripten in totaal bloed het totaal aantal gedetecteerde transcripten toe doet nemen 
en daardoor ook de statistische kracht om relevante ziektesignaturen te ontdekken.
Hoofdstuk 3 beschrijft de resultaten van onze genoomwijde genexpressie studie met 
next generation sequencing in totaal bloed. Tot op heden is onze studie de grootste gen-
expressiestudie in perifeer bloed van ZvH patiënten, met een substantieel aantal pre-
symptomatische patiënten. Verder was onze studie de eerste die gebruik maakte van 
next generation sequencing genexpressie profilering waarbij in het verleden voornameljk 
hybridisatie microarrays gebruikt werden. Onze resultaten bevestigen voor het eerst ee-
rder gepubliceerde data, wat het potentieel benadrukt dat next generation sequencing 
biomarkers kan identificeren die relevant zijn voor de ZvH. We tonen aan dat door het 
toepassen van relevante statistische methodes, genen die niet het meest significant ver-
schillen in expressie, gebruikt kunnen worden voor een biomarker panel voor ziektepro-
gressie. Dit biomarker panel kan bestaan uit een combinatie van genen die complemen-
taire informatie bevatten die specifiek zijn voor de ziekte en niet alleen zijn geselecteerd 
op hun significante expressie. Een dergelijk genenpanel kan zo ontworpen worden dat 
het een betere weerspiegeling is van de pathologie in de verschillende groepen patiënten.
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In hoofdstuk 4 laten we een unieke integratie zien van verschillende soorten data uit 
bloed van ons cohort ZvH patiënten en controles: metabolic data en de hiervoor be-
schreven next generation genexpressie data. Metabolomics kan in potentie veranderin-
gen laten zien die plaatsvinden downstream van genexpressieregulatie in de ZvH. Door 
een getargete metabolomics aanpak konden we op een robuuste en reproduceerbare 
manier veranderingen meten die later in longitudinale studies toegepast kunnen worden. 
Door een multidisciplinaire aanpak en het gebruik van community-driven bioinforma-
tische methoden, konden we de genexpressie data en de metabolomics data van ons 
ZvH cohort met elkaar verbinden. Een dergelijke integratie van data is een van de eerste 
multi-level “omics” die in de toekomst nog verder verrijkt kan worden met additionele 
biologische datasets en zodoende een meer holistische beschrijving van het ZvH feno-
type tot stand kan brengen.
Ten slotte wordt in hoofdstuk 5 een kritische evaluatie gegeven van alle geproduceerde 
data en de conclusies die hieruit getrokken zijn. Welke kennis er is opgedaan in de 
hier- boven beschreven hoofdstukken in de context van onze methodologie en opzet 
van de studies. In het één na laatste deel van dit hoofdstuk worden de beperkingen van 
ieder hoofdstuk beschreven in relatie tot de inherente limitaties van de technische be-
studeringsopzet en de analyseplatforms die gebruikt zijn. Tot slot worden potentiële 
toekomstige onderzoeksmogelijkheden en vernieuwingen die geassocieerd zijn met de 
onderzoeks-opzet, bioinformatische analyse en analytische componenten van iedere in-
dividuele studie besproken.
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